The Texas Medical Center Library

DigitalCommons@TMC
The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses
(Open Access)

The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences

5-2020

Vestigial-like 1 is a shared targetable cancer-placenta antigen
expressed by pancreatic and basal-like breast cancers
Sherille Denae Bradley

Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Immunology and Infectious Disease Commons, and the Medicine and Health Sciences
Commons

Recommended Citation
Bradley, Sherille Denae, "Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by
pancreatic and basal-like breast cancers" (2020). The University of Texas MD Anderson Cancer Center
UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 977.
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/977

This Dissertation (PhD) is brought to you for free and
open access by the The University of Texas MD Anderson
Cancer Center UTHealth Graduate School of Biomedical
Sciences at DigitalCommons@TMC. It has been
accepted for inclusion in The University of Texas MD
Anderson Cancer Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses (Open
Access) by an authorized administrator of
DigitalCommons@TMC. For more information, please
contact digitalcommons@library.tmc.edu.

VESTIGIAL-LIKE 1 IS A SHARED TARGETABLE CANCER-PLACENTA
ANTIGEN EXPRESSED BY PANCREATIC AND BASAL-LIKE BREAST
CANCERS
by
Sherille Denaé Bradley, M.Sc.
APPROVED:
______________________________
Gregory Lizee, Ph.D.
Supervisory Professor
______________________________
Chantale Bernatchez, Ph.D.
______________________________
Amir Jazaeri, M.D.
______________________________
Dorothy Lewis, Ph.D.
______________________________
Gheath Al-Atrash, D.O., Ph.D.

APPROVED:
____________________________
Dean, The University of Texas
MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences

VESTIGIAL-LIKE 1 IS A SHARED TARGETABLE CANCER-PLACENTA
ANTIGEN EXPRESSED BY PANCREATIC AND BASAL-LIKE BREAST
CANCERS
A
Dissertation
Presented to the Faculty of

The University of Texas
Health Science Center at Houston
and
The University of Texas
MD Anderson Cancer Center
Graduate School of Biomedical Sciences
in Partial Fulfillment
of the Requirements
for the Degree of
DOCTORATE OF PHILOSOPHY
By
Sherille D. Bradley, M.Sc.
Houston, Texas, USA
December 2019

ACKNOWLEDGEMENTS
First, giving glory and honor to my Lord and Savior Jesus Christ to whom without I
could not have accomplished this project. Secondly, thank you to my loving husband of 7 years,
Jeremy Sanders, for being my daily support system. Also, thanks to my family for all of their
love, prayers, and support throughout this entire process. Special thanks to my mentor Dr. Greg
Lizee for his guidance and exceptional leadership during both my masters and Ph.D. studies.
Thank you to Dr. Patrick Hwu for always questioning the relevance of my project and
encouraging me to think about the bigger picture as it relates to saving patient's lives.
Thank you to all of my current and past lab mates who have contributed to this project;
Amjad Talukder, Brenda Melendez, Kyle Jackson, Arjun Katailiha , and Heather Sonnemann.
Huge thanks to Dr. Jason Roszik, Dr. David Hawke, and Dr. Cassian Yee for being integral to
the success of this dissertation project. I am incredibly grateful for your help, from teaching me
your methodology, processing data, and your intellectual contributions to my project. In addition,
special thanks to each one of my committee members for sacrificing their time, providing their
insight, encouragement, and challenging me intellectually throughout my Ph.D. studies. Finally,
thank you to the MD Anderson Cancer Center UTHealth Graduates School of Biomedical
Sciences for your resources and in providing well-experienced researchers to work with at this
amazing institution.

iii

VESTIGIAL-LIKE 1 IS A SHARED TARGETABLE CANCER-PLACENTA ANTIGEN
EXPRESSED BY PANCREATIC AND BASAL-LIKE BREAST CANCERS

Sherille Denaé Bradley, M.Sc.
Advisory Professor: Gregory A. Lizee, Ph.D.
Cytotoxic T lymphocyte (CTL)-based cancer immunotherapies have shown great promise for
inducing clinical regression by targeting tumor-associated antigens (TAA). To expand the TAA
landscape of pancreatic ductal adenocarcinoma (PDAC), we performed tandem mass
spectrometry analysis of HLA class I-bound peptides from tumors of PDAC patients. This led to
the identification of a shared HLA-A*0101 restricted peptide derived from co-transcriptional
activator Vestigial-like 1 (VGLL1), a novel putative TAA demonstrating overexpression in
multiple tumor types and low or absent transcript expression in normal tissues with the exception
of placenta. VGLL1-specific CTL isolated and expanded from the blood of a male PDAC patient
showed the capacity to recognize and kill in an antigen-specific manner a majority of HLAA*0101 allogeneic tumor cell lines derived not only from PDAC, but also ovarian, bladder,
gastric, lung and basal-like breast cancers. Gene expression profiling revealed that VGLL1 is a
member of a unique group of cancer-placenta antigens (CPA) that may constitute safe
immunotherapeutic TAA targets for patients with multiple different cancer types. Additionally,
we demonstrate that VGLL1 is associated with poorer patient survival rates in pancreatic cancer.
However, its role in cancer remains largely uncharacterized. VGLL1 shares a similar binding
motif to the TEAD family of genes with the oncogenes, YAP/TAZ that promote malignancies
through the Hippo signaling pathway. We show that VGLL1 may play a significant role in
tumorigenesis by inducing tumor cell proliferation, migration, and invasion.
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CHAPTER I:
INTRODUCTION AND BACKGROUND
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1.1 Introduction to Immunology
Immunology is the study of the immune system and its role in protecting the body
against foreign pathogens and disease [1, 2]. The immune system is comprised of two
main subcategories of immunity, innate and adaptive immunity [2, 3]. Innate immunity is
the body’s first line of defense against foreign entities [4, 5]. The innate response is
immediate non-specific protection made to fight against invading bacteria, viruses, and
fungus [3]. Adaptive immunity, also referred to as specific or acquired immunity, is
created in response to the body’s exposure to these foreign substances over time [6].
Adaptive immunity can be further subdivided into humoral and cell-mediated immunity
[3, 6]. Humoral immunity is regulated by activated B cells through the production of
antibodies, while cell-mediated immunity is carried out by T-lymphocytes cells (T cells).
There are three major categories of T cells: helper, regulatory, and cytotoxic [2]. Within
each of these three categories, there are multiple T cell subtypes. Helper T cells are
primarily CD4+ T cells. Helper T cells produce molecules called cytokines that signal to
other immune cells in response to pathogens that the T cell recognizes. In contrast,
regulatory T cells (T regs) play a role in the suppression of the immune system. T regs
function to protect against the immune system by acting as a shut-off switch when it is no
longer needed [2, 7]. Lastly, cytotoxic T cells (CTLs or CD8+ T cells) are the primary
effector cells of the immune response. CD8+ T cells produce molecules that destroy
foreign pathogens or infected cells once activated.
The power of the immune system can be harnessed to target not just invading
microbes and viruses, but it can also be used as a biologic therapy for the treatment of
cancer. While both the innate and adaptive immune system can be used as therapeutic
2

interventions of cancer, the adaptive immune response plays a vital role in anti-tumor
immunity. As we will discuss further, this is because CTLs are the critical regulators of
the cell-mediated immune response against cancer cells. In the following section, we will
briefly discuss the history of immunotherapy, its various forms, and multiple ways that
the adaptive immune response can be harnessed to treat cancer.
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1.2 Immunotherapy
Immunotherapy aims to induce anti-tumor responses by augmenting immune
surveillance and overcoming mechanisms of immune suppression. In recent years,
immunotherapy has emerged as a viable treatment option for multiple cancers. However,
immunotherapy wasn’t used routinely for many years after its initial discovery due to a lack
of known mechanisms of action and poor reproducibility [8] [9]. The first attempts to
harness the immune system for the treatment of cancer started in the 1890s by William B.
Coley. Coley observed disease remission in patients who were injected with mixtures of live
and attenuated bacteria [10, 11]. Since Coley didn’t know the mechanism of action, and
studies yielded mixed results, immunotherapy remained dormant for many years after this
initial observation (Figure. 1.1). In the late 1950s, Thomas and Burnet played a major role in
bringing immunology to the forefront. They proposed that lymphocytes were mediators of
immunosurveillance by identifying and eliminating somatic cells transformed through
mutations. However, it wasn’t until the 1970s, that Carswell et al., discovered that the
eradication of tumors was a result of tumor necrosis factor production in response to the
bacterial endotoxins [12]. Morales et al. went on to publish their findings in the 1970s
showing, that Bacillus Calmette-Guerin (BCG) could be used to treat bladder cancer [13]. At
this point, immunology was began to be taken seriously as a treatment option [13]. Since
then, many further advances in cancer immunotherapy have led to remarkable improvements
in response rates, progression-free survival, and overall survival in patients.

4

Figure 1.1 History of Tumor Immunology.
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Figure 1.1 The History of Tumor Immunology. A timeline of the origins of tumor
immunology. The timeline includes some of the major accomplishments and discoveries
since its beginnings that has led to advancements in immunotherapy.
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There are several forms of immunotherapy that fall into one of two categories: passive
immunotherapy and active immunotherapy [14]. Active immunotherapies can be nonspecific or specific. Active immunotherapies directly induce an immune response through the
eliciting the host’s endogenous immune system to fight disease [9, 14]. Passive
immunotherapy differs in that it relies on elements constructed in the laboratory, which are
then administered to patients to provide exogenous immunity [15, 16]. Cytokines and
chemokines, such as interleukin-2 (IL-2) and interferon-alpha (IFN-α), are two common
forms of active immunotherapy (Table 1.1) [17, 18]. They can be used to boost the immune
response and lead to increased proliferation of tumor-eliminating T cells and or activation of
disease-fighting cells [17, 19]. Vaccines are another biological agent used to induce antitumor responses. These can include peptide, viral, and dendritic cell-based vaccines [20, 21].
One form of passive immunotherapy involves the transfer of monoclonal antibodies into
patients to target an array of specific antigen targets [22]. Monoclonal antibodies can bind to
surface targets on cancer cells and act as downstream signaling pathway blockers of
proliferation [22]. For example, bevacizumab (Avastin) is an FDA-approved monoclonal
antibody against the growth factor VEGF-A (Table 1.1). However, there are also monoclonal
antibodies that can also be used to inhibit receptors that normally act to halt the immune
response. Examples of such inhibitors are checkpoint blockade therapies, or immune
checkpoint modulators. These antibodies bind to the surface receptors on T cells that
effectively “put the brakes” on T cell activation, blocking them and allowing them to
continue to be active and attack the tumor [23]. Most recently, the Nobel Prize for
Physiology and Medicine was awarded to, Dr. Jim Allison and his colleague Dr. Tasuku
Honjo, for their groundbreaking discovery of cytotoxic T-lymphocyte-associated protein 4
7

(CTLA-4) checkpoint molecules and programmed death (PD-1) respectively [24]. Their
discoveries are perhaps one of the most prominent findings in the last ten years and has
radically impacted the treatment of metastatic melanoma [25, 26].
No matter the type of immunotherapy used, the key to specific anti-tumor immunity lies
within the target. One of the most vital categories of targets of anti-tumor immune responses
are tumor-associated antigens (TAAs). These tumor-specific targets are recognized by T cells
to induce an immune response for tumor elimination [27]. Tumor-associated antigens are
peptides found on the surface of tumors bound to Human Leukocyte Antigens (HLA)
molecules (Figure 1.2). TAAs come in a variety of forms including, glycolpeptides, viral or
bacterial derived-peptides, and phosphopeptides [28]. TAAs can be targeted with multiple
therapeutic options, including cancer vaccines and T cell-based immunotherapies [28].
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Table 1.1 Forms of Immunotherapy.
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Table 1.1 Forms of Immunotherapy. A table displaying current active and passive
immunotherapeutic approaches.
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1.3 Tumor Associated Antigens
The discovery of tumor-associated antigens in the late 1950s revolutionized our
understanding of tumor immunology. Dr. Richmond T. Prehn’s research showed in mice
that an immune response could be mounted against a carcinogen-induced sarcoma that
later protected the mice against future challenges with the same tumor [29] [30]. His
work provided evidence that tumors contained specific target antigens that could induce
immunity and lasting immune memory [30]. These studies were the foundation for work
that has continued to identify human tumor antigen targets. It is known that tumor
antigens can be derived from self-proteins that are either over-expressed, tissue-specific,
or arise due to mutations [27]. Tumor-associated antigen targets must possess some level
of immunogenicity with low immune tolerance in order to be effective targets of CTLmediated immune responses. Figure 1.2 demonstrates a “gradient” of tumor- associated
antigens ranging from non-targetable self-antigens (high tolerance, low immunogenicity)
to antigens (low tolerance, high immunogenicity).
Although most self-antigens are not targetable due to unacceptable toxicity against
normal tissues, there are classes of self-antigens that are potentially targetable [31]. Some
antigens are expressed in specific normal tissues despite being found abundantly in
tumors; these are known as tissue differentiation antigens [31]. One example of a tissue
differentiation antigen is the protein enzyme tyrosinase. It is expressed only by
melanomas and by normal skin cells known as melanocytes [32]. Another class of selfantigens are cancer-testis antigens (CTAs); these include antigens such as MAGE-A and
NY-ESO-1 [33-35]. As the name suggests, they are found in high abundance primarily in
testis tissue and in some tumors. Over-expressed tumor-associated antigens are found in
11

low abundance in multiple normal tissues but are highly over-expressed in tumors. The
protein HER2 is an example of an antigen that is expressed by normal tissues but is
highly overexpressed in multiple cancers, such as breast, gastric, and lung cancers [36].
Neo-antigens are highly tumor-specific antigens that arise from somatic tumorassociated mutations.
These targets are highly sought are the most sought after because of their unique
tumor-specific sequences avoid issues of T cell tolerance and auto-reactivity [37].
Mutated TAAs can originate from frameshifts, deletions, insertions, fusions, and or other
structural rearrangements of proteins [38]. Additionally, oncogenic viruses, such as
human papillomavirus (HPV), can also induce the expression of unique tumor-specific
antigens, which can be exploited as tumor-specific targets [39, 40].
Continued efforts to identify targetable tumor antigens shared by large numbers of
cancer patients remain vital to the current and future success of T cell based cancer
immunotherapies.

12

Schematic of tumor associated antigens

Figure 1.2 Schematic showing different categories of tumor associated antigens gradient.
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Figure 1.2 Schematic showing different categories of tumor associated antigens gradient.

Tumor cell representing the several tumor associated antigens found on its surface. The
figure demonstrates the range from non-mutated (high tolerance, low immunogenicity) to
foreign (low tolerance, high immunogenicity) antigens.
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The discovery of TAAs has led to the development of multiple cancer
immunotherapies, including peptide vaccines and adoptive T cell therapies. For example,
cancer vaccines utilize tumor-associated peptides to prime antigen-specific T-cell responses
in the body and increase the numbers of TAA-specific CTLs. Adoptive T cell therapy
involves the isolation and ex-vivo expansion of tumor-reactive T cells. The benefit that
adoptive T cell therapy has over vaccines is the ability to expand T cells to a greater extent,
then what vaccines alone can accomplish.
Lymphocytes that infiltrate into the stroma of tumor nodules are referred to as tumorinfiltrating lymphocytes (TILs) [41, 42]. TILs provided the first evidence that the immune
system can recognize tumor antigens [43, 44]. In 1988, Wolfel et al. showed that target
structures presented by HLA molecules on tumor cells could induce the killing of these cells
by CTLs [44]. The target structures identified were later described as the first tumor antigens
recognized by T cells [45]. Intracellular proteins are comprised of polypeptide chains, and
within a cell, they are degraded into shorter peptides that can be presented at the cell surface
when loaded onto HLA-I molecules. HLA class I-bound peptides usually range in size from
8 to 12 amino-acids, and are derived from most cell-associated proteins and are recognized
by the T-cell receptor of CTLs [46]. Peptides can only bind to specific HLA alleles that
possess particular amino acid binding motif preferences [46, 47]. The targeting of TAAs
through T cell mediated immunity has been the foundation of modern-day .cancer
immunotherapy. The next section will discuss the role of TAAs in CTL-mediated
immunotherapies.
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1.4 CTL-mediated immunotherapy
Cancer immunotherapies have grown exponentially in recent years and have made
remarkable improvements in patient survival. The adaptive immune response relies heavily
on immune effector cells known as cytotoxic t-lymphocytes. Also referred to as CD8+ T
cells, CTLs are known to be major players in inducing the regression of tumors (Figure
1.3B). CD8+ T cells possess T cell receptors (TCRs) that recognize HLA class I molecules
displaying peptide antigens on all cells in the body (Figure 1.3A). In addition to
distinguishing self-antigens from pathogen-derived antigens, effector CD8+ T cells can also
be primed to target tumor antigens [48].
Several different T-cell based immunotherapies have been developed to treat cancer.
TILs are have set the foundation for the expansion of adoptive transfer of tumor reactive T
cells. The cytokine interleukin-2 (IL-2) is responsible for the growth, proliferation, and
differentiation of T cells to become effector cells. T cells also produce IL-2 in recognition of
a foreign pathogen or a tumor antigen. Dr. Steven Rosenberg found that IL-2 as a
monotherapy was an effective treatment option for metastatic melanoma patients [49, 50]. He
also demonstrated that TILs extracted from melanoma tumors could be expanded ex vivo
with the administration of high dose IL-2 in vitro [51, 52]. IL-2 given as either a
monotherapy or in combination with TILs were some of the first successful T-cell mediated
immunotherapies developed for the treatment of cancers [41, 52].
An alternative form of adoptive T cell therapy involves the isolation and expansion of
endogenous tumor-antigen specific T cells (ETCs) from peripheral blood [50]. ETC
treatment uses the peripheral blood as a source for the isolation of low-frequency, tumor16

reactive T cells [50, 53]. Much like TILs, these T cells can be isolated, stimulated, and
expanded ex vivo to high quantities, then re-administered to cancer patients as a robust form
of therapy [54]. In TIL therapy the specific tumor antigen target is usually unknown at the
time of treatment; thus TIL therapy is usually a highly personalized treatment [55]. ETC
targets specific, known tumor targets and has the potential to be a shared immunotherapy that
can benefit many patients [50].
Tumor antigen peptides can be used to prime tumor antigen-specific T cells in vitro.
Cells also found in the peripheral blood, known as antigen-presenting cells (APCs), primarily
dedritic cells, monocytes, and B lymphocytes are used to activate antigen-specific T cells and
induce proliferation [20, 55]. After in vitro stimulation with peptide-pulsed APCs, antigenspecific T cells expand to billions of cells and used for therapeutic purposes [53]. Once a
tumor-antigen specific T cell deemed to have good anti-tumor activity, the therapeutic TCR
can be cloned and used for TCR engineering, a relatively new treatment [56].
TCRs that have the high affinity for their tumor antigen target can be cloned and
transduced into T cells that normally cannot recognize the target antigen [57]. These
engineered TCR-T cells can be administered to other patients who share the same antigen
target of interest, as well as the presenting HLA molecule. TCR-T based immunotherapy
likely has the potential to reach a much broader patient population.
The first clinical trials using T cell therapies were done in the setting of metastatic
melanomas [50, 58]. Targeting the tumor antigens, MART-1 and gp100, has shown good
clinical activity with TIL and ETC [53, 57]. Some of which have induced complete
responders or induced dramatic regressions in tumors [53, 58]. Although, there has been
17

minimal toxicity noted in these patients, TCR-T therapies against these same antigens have
induced unacceptable toxicities, by killing normal melanocytes. Although antigen-specific
immunotherapies are available for melanoma, many other tumor types have no known TAA,
to target, which represents an important unmet need in the field.

18

Antigen presentation and T cell Recognition

Figure 1.3. T cells recognize antigens bound to and presented by HLA class I molecules.
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Figure 1.3. T cells recognize antigens bound to and presented by HLA class I molecules.
A) Crystal structure of an HLA class I molecule displaying where peptide antigens are
bound. B) HLA class I molecule presenting an unknown tumor antigen to a T cell for
recognition and killing of the tumor.
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1.5 The role of HLA class I molecules in CTL-mediated immune responses
HLA molecules constitute the central focus of the T cell mediated immune response.
HLA class I molecules display peptides display peptides expressed by all nucleated cells of
the body, including self, non-self, pathogen, and tumor-derived to effector T cells. All cells
can present endogenously derived peptides on HLA class I molecules. Specialized APC’s,
such as DC’s can also display exogenously-derived peptides in a process called crosspresentation. Mature HLA class I complexes are assembled in the endoplasmic reticulum
(ER); they are heterodimers assembled from a polymorphic heavy chain, a light chain called
β2- microglobulin (β2m) and an antigenic peptide (Figure 1.4) [59, 60]. Proteasomes
degrade cytoplasmic proteins into smaller peptides, which are transported into the ER by the
transporter associated with antigen presentation (TAP) and are loaded into the peptidebinding grooves of the HLA-I molecules. The HLA-I binding groove accommodates peptides
8 to 12 amino acids in length [59]. In the ER, HLA-I molecules are stabilized by chaperone
proteins such as calreticulin [61]; in addition, the molecule tapasin interacts with TAP to
assist in the delivery of peptides to HLA-I molecules. When a peptide is successfully bound
to HLA-I heavy chain and β2- microglobulin as a trimolecular complex, it exits the ER via
the secretory pathway and travels to the cell surface in vesicles for presentation (Figure 1.4).
Since HLA-I display these peptides at the cell surface, and then they play an essential role in
antigen presentation and T cell surveillance.

21

Figure 1.4 HLA Class I processing and antigen presentation pathway.
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Figure 1.4 HLA class I processing and antigen presentation pathway. Endogenously
derived proteins are degraded, loaded on to HLA molecules, and shuttled to the cell surface
for presentation. HLA molecules can fit specific antigens in their binding groove and present
to T cells on the surface of cells.
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Human CTLs recognize the products of the three classical genes; HLA-A, HLA-B,
and HLA-C. Each HLA type can recognize and bind uniquely to many different peptides
dictated by the molecular properties of the their peptide binding grooves (Figure 1.4) [62].
HLA-A and HLA-B are expressed at higher surface levels in human cells than HLA-C. The
extremely high level of HLA polymorphism results in different peptide-binding grooves that
recognize and bind characteristic peptide sequences, allowing for each individual to present a
wide and distinct array of peptides.
Each HLA-I molecule loaded with peptide is expressed on the cell surface to present
peptides to CD8+ T cells. This can induce clonal expansion of effector of T cells, target cell
killing, or cytokine release, depending on the APC and T-cell differentiation state. Each T
cell contains a unique T-cell receptor that binds to HLA-I/peptide complexes; when this
occurs, many more stabilizing receptors bind to one another from each cell, thus allowing the
T-cell to stay in close contact with the APC. This induces the release of effector molecules
such as Granzyme B and perforin by CD8+ cytotoxic T cells to induce target cell death.
Granzyme B is a serine protease and perforin is a pore-forming protein that facilitates it’s
entry into target cells; once inside, it triggers an increase of intracellular calcium that
eventually leads to the apoptosis of target cells [61, 63].
The antigenic landscape of tumors, or immunopeptidome, is the collection of the
peptides are presented by HLA molecules [64]. By analyzing the immunopeptidome of
cancers, researchers have discovered novel TAA targets to facilitate the treatment of cancer.
Multiple methods have been used for tumor antigen discovery, but in recent years mass
spectrometry analysis has proven the most useful for high-throughput.The following section,
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will discuss how mass spectrometry-based antigen discovery has made major strides in
cancer immunotherapy.
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1.6 Mass spectrometry-based antigen discovery

In recent years, there have been significant improvements in the field of proteomics,
the large-scale study of proteins. Coupled with technological advances in genomics,
bioinformatics, and prediction platforms, these tools have greatly facilitated
immunopeptidome discovery [64]. For many years, the most commonly used method for
tumor antigen discovery was in-silico based [65]. The use of computer programs and
prediction software has been the primary methodology for HLA-I binding prediction, but
these methods as a single form of identification have several limitations.
In-silico approaches to identify tumor antigens rely on peptide sequences that have
been eluted from different HLA alleles [66], [65]. Together with binding affinity algorithms
that are derived from in-vitro binding assays, these tools are capable of predicting potential
tumor antigen sequences that may be viable HLA-bound targets. They are also are capable of
identifying possible neo-antigens peptides [67]. However, neo-antigen discovery is much
more challenging and costly since it requires massive amounts of DNA and RNA sequencing
data from both normal and tumor tissues that must be analyzed for non-synonymous
mutations [64, 68]. These mutated protein variants are then translated into amino acid
sequences in silico and analyzed with HLA peptide binding programs against all known HLA
alleles [68]. Examples of these programs include NetMHC or EpitoolKit. If potential
antigens are identified, synthetic neo-antigens can be used to conduct T cell screening assays
for potential reactivity [68, 69].
Mass spectrometry (MS) can be used as a more direct form of tumor antigen
discovery that is both unbiased and comprehensively investigates the entire peptide repertoire
of a given tumor sample [64]. This sample may be a solid tumor specimen, cell line, or even
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bodily fluids. The current process of MS-based antigen discovery starts with
immunoprecipitation (IP) of HLA class I complexes from solubilized lysates [64]. IP’s are
typically conducted with pan-HLA class I or pan-HLA class II antibodies [68]. However,
HLA-allele specific antibodies can also be used as well. The peptides are eluted in low PH
and are separated by high-pressure liquid chromatography and injected into a mass
spectrometer for analysis [68]. The results are searched against publicly-available protein
databases, using serch tools such as Mascot or MaxQuant [70].
One of the benefits of MS over in-silico methods is the high-throughput [64].
Depending on the size of sample, up to thousands of potential tumor antigen targets can be
detected in less than 2 hours. Additionally, targeted-MS, a process that adds a higher level of
fractionation of the sample, can increase the depth at which the sample is analyzed and
provide greater sensitivity. Targeted-MS enables more accuracy and reproducibility for
specific peptides of interest [71, 72]. Typically, target-MS is used as a secondary method
after a sample has been analyzed in discovery mode. Thus, it is more suited for peptide
validation, rather than discovery.
There are several databases that are used to help to determine the targetability of MSeluted peptides. The Swiss-Prot is a database that complies the information from scientific
literature and computational analyzes on human protein sequences [73, 74]. The database is
used to search for MS-eluted peptides to provide any relevant information on proteins.
Additional validation and vetting of MS-eluted peptides can be determined by evaluating the
expression of peptide-encoding genes in primary tissues and tumors. Normal tissue transcript
expression determined by RNA sequencing is found in the Genotype-Tissue expression
(GTEx) Portal database. Overall patient tumor tissue expression is available in the The
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Cancer Genome Atlas (TCGA) database. TAAs found to be highly expressed in normal
tissues according to the GTEx are immediately eliminated as potential therapeutic targets.
While, TAAs that are highly over-expressed in tumors with low expression in normal tissues
can be further evaluated. HLA-I peptide prediction binding algorithm databases are also used
to add another level of confidence that eluted peptides are presented on the surface of the
tumor. These HLA-I algorithms provide information on the predicted binding affinity of each
peptide, indicating if the peptide weakly or strongly binds to HLA alleles. Together, these
databases allow for in-depth analysis of MS-eluted peptides to determine if they are suitable
therapeutic targets.
Currently, MS-based antigen discovery has expanded the immunopeptidome
landscape many tumor types, including melanoma, hepatocellular carcinomas, leukemia, and
renal cell carcinomas [69, 75]. It has primarily been used to discover shared antigens, but
now researchers are also using this method to detect neo-antigens for personalized therapies
or shared neo-antigen epitopes [76]. This method of detection is currently being developed
for neo-antigens but has yielded some positive results in highly mutated cancers, like lung
cancer and melanomas [77, 78]. There remain limitations to sensitivity, and these analyses
require large sample sizes.
MS-based antigen discovery coupled with in silico methods has helped to expand the
targetable immunopeptidome landscape of multiple cancers. HLA prediction binding
algorithms, in particular have served as an important validation to vet eluted peptides.
MS-based antigen discovery has also helped to improve HLA class I binding algorithms for
future researchers. The development of these methods, has allowed us to analyze additional
cancers that have historically poor response rates to the current standard of care options.
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Cancers types such as ovarian and pancreatic cancer for example have a lack of alternative
treatments once patients fail to respond to front line treatments. This forms the rationale for
this dissertation work, as will be discussed future in the following section.
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1.7 Long term goal and rationale for this dissertation

The long-term goal of this dissertation was to develop a novel and effective cytotoxic
T cell-based immunotherapy for cancer patients. Through this work, we aimed to identify
shared tumor antigen targets in two cancers that have poor response rates to the current
standard of care therapies, ovarian cancer and pancreatic cancer. Although, tumor associated
antigen discovery is feasible for these cancers, to date there remains no T cell-based
immunotherapeutic options for these patients. Cancer vaccines have been the primary
objective of previous studies, but these have not provided benefits in the overall survival
rates of these patients. There a few ongoing clinical trials using CAR T cells against a select
few antigen targets for ovarian cancer. However, the trials are still very early, and have yet to
show any promising results. Thus, there remains an un-met need to identify and validate
viable tumor associated antigens in these cancers to faciliate T cell-based immunotherapies.
We chose to focus our efforts on the identification of non-mutated, overexpressed
antigens in ovarian and pancreatic cancer. Our goal was to identify a shared tumor-associated
antigen with little to no expression in normal tissues. If the TAA was also shared amongst
both or additional cancer types, that was also ideal. Finally, we took into consideration the
diversity of the HLA types from our patient samples, aiming to find epitopes from HLA
alleles expressed at a high frequency in the worldwide if population. Due to our clinical
collaborators, we had the rare opportunity to have access to fresh patient tumor samples for
our studies. Additionally, we the expertise and knowledge on how to utilize massspectrometry based tumor antigen, where we used this method to identify tumor antigen
targets in melanoma. Using high-throughput tandem mass spectrometry, we successfully this
method to identify the tumor associated antigen, SLC45A2 [79]. In collaboration with a
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bioinformatics expert and our clinical collaborator, we also were able to validate the peptide
target and then isolate low-frequency endogenous, T cells from the peripheral blood of
healthy donors. Furthermore, we were able to show that these SLC45A2-specific T cells
could recognize and eliminate tumors that expressed the target gene and the appropriate HLA
types. This is now the basis for an ongoing clinical trial for uveal melanoma patients. The
work in this dissertation applies the same antigen discovery concepts to ovarian and
pancreatic cancers, leading to the discovery of Vestigial-like 1 (VGLL1) as a potentially
targetable TAA for multiple tumor types.
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1.8 Overall hypothesis and Specific Aims

It was our central hypothesis that the accurate identification and selection of
appropriate tumor associated antigens in ovarian or pancreatic cancer, would provide a
foundation on which to develop a novel and effective T-cell based immunotherapy. In this
dissertation we tested this hypothesis through fulfilling the following aims:

AIM 1. Identify tumor-associated antigen-encoding genes from patient tumor
specimens.
Aim 1.1. Perform HLA class I-bound peptide elution and mass spec analysis of patient
specimens to identify potential tumor-associated peptides.
Aim 1.2. Select best shared tumor-associated target peptides utilizing bioinformatics
algorithms.
AIM 2. Generate antigen-specific cytotoxic T-cells against validated peptides and
expand the shared tumor-associated target repertoire.
Aim 2.1. Validate best peptide candidates and generate antigen-specific CTLs against
selected targets.
Aim 2.2. Test the specificity and cytotoxicity of generated CTLs using HLA-matched tumor
cell lines and primary cell lines.
Aim 2.3. Identify shared TAA targetable tumors by testing the generated CTLs against
additional HLA-matched TAA-expressing tumor types.
AIM 3. Characterize the role of the identified tumor-antigen VGLL1 in cancer
progression.
Aim 3.1. Utilize siRNA and lenti-viral vectors to generate knockdown and overexpressed
VGLL1 tumor cell lines, and analyze morphological changes in transduced tumor cells.
Aim 3.2 Explore the role of VGLL1 as a promoter of cancer progression by examining
VGLL1 over-expressing and knockdown tumor cells for proliferation, migration, and
invasion of the tumor cells.
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CHAPTER II:
OVARIAN CANCER TUMOR ASSOCIATED ANTIGEN DISCOVERY
AND T CELL GENERATION

33

2.1 Rationale for tumor antigen discovery in ovarian cancer
Our first aim sought to delve into the immunopeptidome landscape of ovarian cancer
(OVCA) to identify viable tumor antigen targets. Specifically, we sought to target the most
aggressive and deadly form of OVCA, epithelial ovarian cancer (EOC) [80]. Epithelial
ovarian cancer is the leading cause of death among gynecological cancers and has been
coined the “silent killer” [81-83]. The current five-year survival rate for EOC patients is
about 44%, due primarily to its metastatic nature and late-stage diagnosis [80, 83, 84]. The
common symptoms of ovarian cancer are similar to other gastrointestinal and gynecological
conditions and thus are often are not easily attributed to the early diagnosis of ovarian cancer
[81, 85].
The current standard-of-care relies on surgical tumor debulking followed by cisplatinbased chemotherapy [86]. Despite the high rate of initial responses, acquired cisplatin
resistance in ovarian cancer remains a significant roadblock to the successful treatment of
patients. Currently, immunotherapy for EOC is only considered after patients have failed
front-line therapy [81, 87]. Several clinical trials using adoptive T cell including TILs and
CAR-T cells have been conducted or are underway. Immune checkpoint inhibitors, antiVEGF, and poly (ADP-ribose) polymerase (PARP) inhibitors are also being tested clinically
[88, 89].
The presence of tumor-infiltrating lymphocytes (TILs) in EOC patient tumor samples
does show an increased correlation with progression-free survival and overall patient survival
[90]. This suggest that a T-cell based immunotherapy may potentially improve patient
outcomes. EOC is known to have a highly immunosuppressive environment, similar to
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pancreatic cancer [91, 92]. Therefore, EOC immunotherapies may need to be combined with
additional anti-tumor approaches to achieve full treatment efficacy.
Adoptive T cell therapy approaches have been used in clinical trials for EOC [93].
Most notably, TIL therapy has had some mixed but mostly promising results. TILs promote
tumor regression in patients with either advanced disease or recurrent platinum-resistant
cancer [94]. However, toxicity remains an issue with EOC patients. As a single treatment,
platinum-based chemotherapy is very toxic to patients [95]. In clinical trials, the combination
of TILs and cisplatin, even without IL-2 still resulted in unfavorable toxicities [95].
Overall, clinical data supports the notion that the presence or absence of TILs does
have a significant impact on response rates of patients [96]. This does bring up the question
of what exactly are the TILs recognizing? Additionally, how can we boost this anti-tumor
response? Are there potentially shared target antigens present in these EOC patient tumors?
Having a better understanding of the antigen targets presented by these tumors could improve
the outcome for EOC patient survival.
The next section will discuss how tandem mass spectrometry was utilized to analyze
fresh ovarian tumor specimens derived from patients at M.D. Anderson Cancer. In
collaboration with Dr. Amir Jazaeri in the M.D. Anderson Gynecological Oncology
department, we analyzed over 30 ovarian tumor samples derived from patients. To identify
tumor-associated antigens, we performed HLA class I immunoprecipitation and acid elution,
followed by mass spectrometry analysis to identify HLA-bound peptides found within the
tumor samples.
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2.2. Ovarian cancer MS-based TAA discovery and antigen-specific T cell generation
2.2a.) Identification of ovarian cancer TAAs from fresh patient tumor specimens.
In the first aim, our goal was identifying appropriate target genes through direct proteomic
analysis of OVCA patient tumor samples. To achieve this, we analyzed OVCA tumor
samples from freshly excised patient biopsies obtained from our MD Anderson surgical
collaborator Dr. Amir Jazaeri. We lysed the tumor specimens, and then performed
immunoprecipitation of HLA class I molecules, and followed by acid elution of HLA-bound
peptides. Next, we utilized tandem mass spectrometric analysis to identify tumor-associated
peptide antigens, as shown in (Figure 2.1).
In tandem mass spectrometry, individual fragmented peptides ions are displayed as a
mass spectrum. The full length peptide backbone is fragmented into b and y ions. The
spectrum consists of peaks corresponding to each fragmented ions mass-to-charge (m/z) ratio
values (Figure 2.2). Multiple copies of the same peptide can be within the sample, and the
relative intensity of the fragmented ions is depicted on the y-axis. Higher quality spectra
contain more of the ion fragments. The spectra fragments are matched against Swiss-port
databases to determine the theoretical full-length peptide identity.
In total, we completed peptide elutions on 38 fresh OVCA tumor specimens. Nearly
all of the samples were collected from high-grade epithetical ovarian cancer patients, with the
exception of two patients (Table 2.1). Additionally, the site of where the tumor was collected
varied but was mainly derived from the omentum, which is an indication of advanced disease
and metastasis (Table 2.1). The majority of the patients also underwent HLA typing to
determine their HLA allelic expression, an important step in validating our MS results. This
allows for peptide binding predictions of eluted peptides (Table 2.1).
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Peptide Identification from Fresh Tumor
Samples by Mass Spectrometry Analysis

Figure 2.1. Peptide Identification from Fresh Tumor Samples by Mass Spectrometry Analysis.
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Figure 2.1. Peptide Identification from Fresh Tumor Samples by Mass Spectrometry
Analysis. Patient tumor samples containing surface bound HLA-I molecules were extracted,
lysed, and acid washed to eluted the peptides. The eluted peptide samples were then analyzed
by mass spectrometry analysis for the identification of peptides found within the sample. The
peptide ions are separated by mass/charge, then the ions are fragmented, and laser then
detects the ions. A mass spectrum is the final output for fragmented peptides detected within
the sample.
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MS/MS mass spectrum

Figure 2.2. Example of a MS/MS mass spectrum.

Figure used with premission from author:

Hughes, C., Ma, B., Lajoie, G.A. De novo Sequencing Methods in Proteomics. Methods Mol
Biol. 2010;604:105-21.

39

Figure 2.2. Example of a MS/MS mass spectrum. The spectrum is a mass spectrometry
output that displays the fragmented peptide ions within a sample. The theoretical peptide is
fragmented into b and y ions, which are measured by their relative abundance and mass-tocharge ratios.
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Table 2.1 Ovarian tumor sample list.
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Western Blot of Immunoprecipitated HLA class I

Figure 2.3. Representative image of an HLA immunoprecipitation validation by
Western blot analysis from three ovarian cancer patients.
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Figure 2.3. Representative image of an HLA immunoprecipitation validation by
western blot analysis. Western blot of 3 different ovarian patient tumor sample HLA
immunoprecipitations. Samples were stained with the pan-class I antibody W6/32 to
determine the relative abundance of HLA-I found within the lysed tumor sample prior to
mass spectrometry analysis.
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All HLA immunoprecipitations were validated by Western blot analysis to determine
if the HLA class I protein concentration was sufficient and was comparable between each
sample. Figure 2.3 is a representative figure of a peptide elution validation by Western blot
analysis. We identified roughly 500 to 1500 peptides on average per tumor sample.
To assess the most frequently eluted peptide-encoding genes found in the OVCA
immunopeptidome, we analyzed 20 of the best peptide elutions. Figure 2.4 displays the top
50 most frequently eluted peptide-encoding genes among these samples. Through this
unbiased observation of the most frequently eluted peptide-encoding genes, it was revealed
that majority of the peptide-encoding genes eluted are not therapeutically safe antigen
targets.
Finding TAAs with only limited or no cross-reactivity with primary tissues remained
our primary goal in the selection of potential tumor antigen targets. We found that most of
the samples expressed peptides from genes that are un-targetable due to their high expression
in normal tissues. These peptides may show up in high abundance because of the size of the
protein they encode for, or due to the high abundance of the protein in specific tissues. For
example, we found that the gene that encodes for the protein Titin (TTN) appeared in our
OVCA elutions significantly more than any other gene. Titin is a very large protein found in
cardiac and muscle tissues, which is likely why Titin-derived peptides were found so
frequently in our elutions. By utilizing the Genotype-Tissue Expression Portal (GTex)
database, which contains RNA sequencing on samples collected from 55 primary tissue sites
from >3000 individuals, we can further analyze the therapeutic safety of each gene.
The relative RNA transcript expression of a gene in each tissue can be represented in
transcripts per million (TPM). TPMs can range from zero, which is essentially no transcript
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expression, up to the thousands indicating extremely high gene expression. We were
specifically searching for TAAs that have the lowest expression in normal tissues. Zero
TPMs represents ideal transcript expression in primary tissues. However, the vast majority of
peptides we eluted were derived from genes that also had some level of transcript expression
in normal tissues.
Primary tissues from the GTex were split into four safety categories that reflected the
potential toxicities expected from off-target killing activity by antigen-specific CTLs (Table
2.2). These categories ranged from extremely dangerous (essential), hazardous, dangerous,
and likely okay (non-essential). Table 2.2 contains examples of some of the normal tissues
within each category along with the acceptable TPM thresholds for each category transcripts.
All peptide-encoding genes were screened based on their TPM expression in each of the
GTex normal tissues. Tumor-associated antigen transcript expression up to 30 TPM
maximum was allowed in non-essential tissues (such as prostate, breast, and adipose tissues).
A maximum expression threshold of 1 TPM was imposed for highly essential tissues such as
heart and brain, for which CTL recognition can be lethal [97], [98].
As observed with TC –T targeting of MAGE-A3, lethal cross-reactivity with other
peptides that share similar sequences is a serious concern [97, 99]. To provide additional
validation for our selected high-confidence peptide matches, they were analyzed by BLAST
searches to identify all potential source genes. This helped to eliminate peptide candidates
derived from multiple genes that may induce cross-reactivity. However, it is not currently
possible to identify all potential peptide cross-reactivies in silico.

.
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Top 50 eluted peptide-encoding genes from OVCA tumor specimens

Figure 2.4. Unbiased look at the top 50 genes encoding for the most frequently eluted
peptides in OVCA.

Figure 2.4. Unbiased look at the top 50 most frequently eluted peptide-encoding genes
in OVCA. Graph displaying the top 50 peptide-encoding genes eluted from 20 ovarian
cancer tumor samples.
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Maximum RNA Transcript Thresholds for TAA expression in Normal Tissues

Extremely
Dangerous
Tissues

Hazardous
Tissues

Dangerous
Tissues

Likely Okay
Tissues

Heart, Brain

Liver, Kidney,
Colon, Lung,
Stomach

Esophagus,
Whole Blood ,
Bladder,
Pancreas

Breast, Testis,
Skin, Ovaries

1 TPM or lower

3 TPM or lower

10 TPM or lower

30 TPM or lower

Table 2.2 Potential toxicity of TAAs based on primary tissue TPM expression. Table
displaying the RNA transcript expression thresholds cutoffs for potential TAA in normal
tissues.
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Examining GTEx normal tissue gene expression, we concluded that Titin was clearly
not a safe targetable tumor antigen [97]. Despite its significant abundance in our OVCA
tumor sample elutions (Figure 2.5). Titin is expressed >300 TPM in skeletal muscle and >50
TPM in the heart muscle. Since our dangerous threshold cutoff for the heart tissues was 1
TPM the expression of Titin eliminated it as a potentially safe therapeutic TAA.
Although the GTex provided some insights into gene expression for primary tissues,
putative TAA genes were also screened for expression and in different cancer types through
analysis of The Cancer Genome Atlas (TCGA) RNA sequence database. The TCGA contains
whole exosome and RNA sequencing data from over 20,000 patients with over 35 different
cancer types (Table 2.3).
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Expression of Titin in normal tissues

Figure 2.5. Expression of the gene Titin in normal tissues.

Figure 2.5. Expression of the gene Titin in normal tissues. RNA expression of the gene Titin in normal
tissues. The x-axis displays the transcripts per million. The y-axis displays the primary tissues. Data Source:
GTEx Analysis Release V8.
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Abbreviation

Cancer Type

LAML
ACC
BLCA
LGG
BRCA
CESC

Acute Myeloid Leukemia
Adrenocortical carcinoma
Bladder Urothelial Carcinoma
Brain Lower Grade Glioma
Breast invasive carcinoma
Cervical squamous cell carcinoma and
endocervical adenocarcinoma
Cholangiocarcinoma
Chronic Myelogenous Leukemia
Colon adenocarcinoma
Controls
Esophageal carcinoma
FFPE Pilot Phase II
Glioblastoma multiforme
Head and Neck squamous cell carcinoma
Kidney Chromophobe
Kidney renal clear cell carcinoma
Kidney renal papillary cell carcinoma
Liver hepatocellular carcinoma
Lung adenocarcinoma
Lung squamous cell carcinoma
Lymphoid Neoplasm Diffuse Large B-cell
Lymphoma
Mesothelioma
Miscellaneous
Ovarian serous cystadenocarcinoma
Pancreatic adenocarcinoma
Pheochromocytoma and Paraganglioma
Prostate adenocarcinoma
Rectum adenocarcinoma
Sarcoma
Skin Cutaneous Melanoma
Stomach adenocarcinoma
Testicular Germ Cell Tumors
Thymoma
Thyroid carcinoma
Uterine Carcinosarcoma
Uterine Corpus Endometrial Carcinoma
Uveal Melanoma

CHOL
LCML
COAD
CNTL
ESCA
FPPP
GBM
HNSC
KICH
KIRC
KIRP
LIHC
LUAD
LUSC
DLBC
MESO
MISC
OV
PAAD
PCPG
PRAD
READ
SARC
SKCM
STAD
TGCT
THYM
THCA
UCS
UCEC
UVM

Table 2.3 List of TCGA cancer types
50

By assessing the TCGA tumor expression data relative to the GTex normal tissue
expression, an TAA over-expression index was calculated (Figure 2.6) (OV-index). The OVindex took into account the average TPM expression of the eluted peptide-encoding genes in
tumors divided by the max TPM expression in essential tissues. This allowed for the filtering
out of the high-confidence potentially dangerous peptide targets from the peptides that may
be safer to target with T-cell based immunotherapies.
For validation, each eluted peptide was also further assessed for several parameters
using bioinformatics algorithms, including Mascot Ion Score, MS1 mass differential (delta
mass), and predicted binding to the patient’s HLA allotypes, as determined by highresolution HLA typing [100], [101]. The Mascot Ion score indicated how well the
experimentally-derived sequence matches the database sequence. Ion scores typically ranged
between 0-90. Only ion scores of 10 or greater were considered, with the best-matched
peptides having scores >25. The delta mass is a measure of the deviation between the
measured peptide mass and the theoretical mass of the peptide, and is important for quality
control. Delta masses between -3 and 3 ppm were considered high quality identifications, and
peptides outside of this ran were excluded from further consideration [102].
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Figure 2.6. Formula used for the calculation of overexpression index.

Figure 2.6. Formula used for the calculation of overexpression index. The average TPM expression of
the eluted gene in tumors divided by the max TPM expression in essential dangerous tissues determined the OVindex.
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The NetMHC and NetMHCpan algorithms determined predicted HLA binding of the
peptides. A low nM affinity score indicates a stronger binding affinity for that peptide to a
particular HLA allele. After selecting high-confidence peptides, targeted MS/MS analysis
was sometimes performed to confirm the TAA peptide identity. As described in chapter I,
targeted MS/MS allows for a more sensitive level of detection with higher-condifidence. To
validate peptides, we combined targeted MS/MS with the isotope labeling of the individually
selected high-confidence peptides. In this process, we started by synthesizing a 13C/15N
isotope-labeled synthetic peptide from the high confidence peptide candidates selected.
The isotope-labeled peptide is analyzed by mass spectrometry along with the original
unlabeled tumor-derived peptide. The mass spectra of the unlabeled and labeled peptide are
matched against each other, while also taking into account the retention-window time. The
retention-window time is an output that measures the time from injection to detection of a
peptide. For peptide validation, both peptides should have similar, if not exact retentionwindow times. Additionally, the peptide-derived spectra should be matching with the
exception of shifted ion mass-to-charge ratios characteristic of the isotope-labeled peptide.
The following section will discuss the candidate TAAs identified through our OVCA
antigen discovery methods, and delve deeper into one specific peptide-derived from MUC16
that was selected as a potentially safe therapeutic target based on the criteria outlined above.
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2.2b.) A novel MUC16-derived peptide was identified in ovarian cancer
From our screening and validation method, a total of 8 TAA peptides were identified
from the 38 OVCA tumor specimens. Five of these peptides were from the gene, Mucin 16
(MUC16) (Table 2.3); however, each peptide identified was from different patient OVCA
tumor samples. We also identified three novel peptides encoded by mesothelin (MSLN).
Although MSLN has been pursued as a TAA in CTL-based and peptide vaccines trials, we
ultimately decided against pursuing it [103-106]. Due to MSLN’s elevated expression in
normal lung tissue at (88 TPM), Thus it was not deemed a safe target according to our
criteria.
From the five peptides that we identified, we chose to pursue the HLA-B*07:02restricted peptide derived from MUC16. The spectra for this MUC16-derived peptide,
TPGGTRQSL, is shown in (Figure 2.7). We selected this TAA target for multiple reasons:
First, the MUC16-derived peptide TPGGTRQSL was found in an OVCA sample and in a
pancreatic tumor specimen from a patient expressing HLA-B*07:02. Additionally, the
MUC16-dervided peptide, TPGGTRQSL was also found in another HLA-B*0702 ovarian
tumor sample by Schuster et al. [107]. Detecting this peptide in another patient with a
different cancer type, suggested that it might be a shared tumor antigen target. This added
another level of confidence to this peptide as a potentially valuable therapeutic target. The
predicted high binding affinity to HLA-B*07:02 (16nM) also contributed to our confidence
that this peptide might be expressed in these tumor types (Table 2.3).
MUC16 was first isolated by MD Anderson’s own Dr. Robert Bast in 1981 [108]. It
is the largest membrane-associated mucin, being over 22,000 amino acids in length. MUC16
is expressed at very low levels in adipose tissue, the cervix, and salivary glands. However,
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MUC16 is expressed under 1 TPM for all these tissues, while being highly over-expressed in
several cancers, including ovarian, pancreatic, cervical, uterine, mesothelioma and lung
(Figure 2.8).
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Table 2.3. List of potential TAA-targets eluted from OVCA tumor specimens.
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Figure 2.7. Mass spectra of MUC16-derived peptide TPPGTRQSL.

Figure 2.7. Mass spectra of MUC16-dervied peptide TPPGTRQSL. Mass spectra of an HLA-B*0702restricted MUC16-derived peptide isolated from an ovarian cancer tumor specimen OV16-012.
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Figure 2.8. MUC16 mRNA transcript expression in normal tissues and tumors.
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Figure 2.8. MUC16 mRNA transcript expression in normal tissues and tumors. GTex mRNA
transcript expression of MUC16 in normal tissues color-coded by extremely dangerous essential
tissues (red), hazardous (orange), dangerous (yellow), and non-essential (green). This is versus the
TCGA mRNA expression of MUC16 in multiple tumor types shown in grey.
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The MUC16 gene and protein has a long history with ovarian cancer. MUC16
(CA125) is an established biomarker for epithelial ovarian cancer progression [109, 110].
MUC16 also contains a proteolytic cleavage site that allows for a major portion to be
released from the cell surface [111]. Circulating serum levels of MUC16 are monitored in
EOC patients as a prognostic factor to determine if patients are responding to treatment or if
there is a recurrence [112]. Since MUC16 is a self-antigen, the ability for MUC16 to detach
from the surface of tissues and circulate may contribute to T cell tolerance. This possibility
was something we considered might be a hindrance to our ability to isolate MUC16-specific
T cells from the blood. Aside from MUC16 being a biomarker for EOC, it also is linked to
ovarian and pancreatic cancer progression through its adhesion to epithelial mesothelinexpressing cells. This interaction promotes the migration, invasion, and metastasis of these
cancers [113-115]. This occurs through the upregulation of the cell motility protein, MMP-7,
via the MAPK pathway [116]. Since MUC16 appeared to be a safe TAA target based on its
low normal tissue expression, combined with its high over-expression in multiple cancers, we
next proceeded to attempt to isolate T cells against the peptide TGGTRQSL.
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2.2c.) Generation of MUC16-specific T cells from healthy donor peripheral blood
To generate MUC16-specific T cells, we utilized guidance from our clinical
collaborator, Dr. Cassian Yee, who has previously developed this protocol [114]. Our
MUC16-derived peptide was restricted to HLA-B*07:02, but we also utilized an HLAA*02:01 MART-1 peptide as a positive control. The MART-1 peptide was used to generate
MART-1 specific T cells alongside the generation of MUC16-specific T cells to ensure the
protocol worked as expected. We began with a leukapheresis obtained from a healthy donor
who expressed both HLA-A*02:01 and HLA-B*07:02 positive alleles.
Donor PMBCs were stimulated twice with autologous dendritic cells (DCs) pulsed
with either the MART-1 or MUC16 (TPGGTRQSL) peptide in the presence of IL-21.
Following the two stimulations, the cultured cells were stained and sorted with either a
MART-1/HLA-A*02:01 or MUC16/HLA*B07:02-PE-conjugated custom tetramer. The cells
were also stained with CD8+ antibody to sort out tetramer-positive CD8+ T cells. The cells
were analyzed by flow cytometry for double-positive cells. Following the stimulation doublepositive MART-1 cells presented at frequency of 18% , a relatively high frequency (Figure
2.9). This indicated that this donor might possess a higher than normal frequency of MART1-specific T cells, compared to the average person. By contrast, after the stimulation,
MUC16-specific T cells were barely detectable at, 0.069% (Figure 2.9).
We sorted cells from multiple culture wells for each peptide and pooled the wells
together to expand the sorted cells in a 12-day Rapid Expansion Protocol (REP). We
obtained a total of 34,000-sorted MART-1 cells and 4,300 cells for MUC16. After REP and
an additional sort for double-positives (DPs), we were able to expand the MART-1-specific
T-cells to 35% DPs, but did not detect any MUC16-specific cells (Figure 2.9). Since
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MUC16-specific T cells did not expand (Figure 2.9). This was an indication that potential
high tolerance and low immunogenicity could be hindering our ability to isolate MUC16specific T cells. Despite these results, we opted to repeat this protocol with modifications
using the same PBMC donor.
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MART-1 and MUC16-specific T cells Generation

Figure 2.9. First approach for the generation of MART-1 and MUC16-specific T cells.
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Figure 2.9. First approach for the generation of MART-1 and MUC16-specific T cells. (A)
Figure 2.9. Generation of MART-1 and MUC16-specific T cells.
Schematic outlining the experimental procedure for generating antien-specific CD8+ T-cells from human
donor PBMCs. (B) PBMCs isolated by leukapheresis were stimulated with autologous MART-1 and
MUC16-peptide-pulsed dendritic cells (DCs). After two stimulations CD8+ and MART-1 (middle row)
and MUC16 (bottom row) tetramer-positive cells were sorted and expanded using a standard rapid
expansion protocol (REP).
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To increase the activation and expansion of low-frequency CD8+ T cells within the
donor PBMCs, Lipopolysaccharide (LPS), a TLR4 ligand, was added during the two DC
stimulations. Following the stims, the cells were stained for double MART-1 or MUC16
tetramer and anti-CD8. Based on the MART-1 staining (13.6%) it appeared that the LPS did
not make a significant difference in the amount of MART-1 specific cells isolated. In this
experiment a total of 42,000 MART-1 HLA-A*02:01 CD8+ T cells were collected. For the
TAA MUC16, we still were not able to isolate very many double-positive cells. In total, we
collected 9,826 MUC16-specific CD8+ T cells for the REP. After the 12-day REP, we
successfully generated >95% tetramer-positive MART-1 specific T cells (Figure 2.10). This
was a significant improvement over the initial attempt. However, MUC16-specific T cell
generation did not fare as well, as we were unable to isolate substantial amounts of MUC16
tetramer-positive CD8+T cells (Figure 2.10). However, after the initial REP we did proceed
to undertake a second REP. Unfortunately, upon completion of the second 12-day REP, the
number of double-positive MUc16-speific T cells was still inadequate for the purposes of
studying their antitumor activity and therapeutic potential.
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MART-1 and MUC16-specific T cells Generation

Figure 2.10. Second attempt at the generation of MART-1 and MUC16-specific T cells.
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Figure 2.10. Second approach for the generation of MART-1 and MUC16-specific T cells.
Generation of MART-1 and MUC16-specific T cells. (A) PBMCs isolated by leukapheresis were
stimulated with autologous MART-1 and MUC16-peptide-pulsed dendritic cells (DCs). After two
stimulations, CD8+ and MART-1 tetramer-positive cells were sorted and expanded using a standard
rapid expansion protocol (REP). (B) MUC16 1 tetramer-positive cells were sorted and expanded using a
standard rapid expansion protocol (REP). A second REP was conducted following a low yield of the first
REP.
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2.2d.) Discussion
MUC16 is a well-characterized tumor-antigen originally discovered in ovarian cancer
[108]. That has been a biomarker for the disease several for years. In addition, it is also a
biomarker for multiple other cancers including, fallopian tube, endometrial, non-small lung,
breast, gastrointestinal, and pancreatic cancers [117-119]. MUC16 plays a critical role in
ovarian and pancreatic tumor invasion and metastasis [109, 115]. For several reasons,
MUC16 fits the criteria of a safe therapeutic target for T-cell based immunotherapy. It has
extremely low expression in normal tissues across the body while having elevated levels in a
number of different cancer types. However, attempting to isolate low-frequency T cells from
the peripheral blood of a healthy donor, was challenging, which may explain why there are
no currently-approved TCR therapies that target MUC16 [120], [121].
MUC16 presents some of the same challenges we face in targeting non-mutated,
over-expressed tumor antigens. MUC16 is unique in that happens to be the largest known
cell surface glycoprotein (at over 22,000 amino acids), with >50 extracellular tandem repeat
domains [122],[123]. This presents a potential explanation for difficulties we experienced in
breaking tolerance. Due to the large size of MUC16, it may share similar or matching
stretches of amino acids with other mucins or proteins that are not safely targetable. All these
factors may be contributing to the lack of immunogenicity of MUC16.
Isolating high-affinity CTLs that recognized MUC16 proved too to be unsuccessful,
even after adding LPS to help boost the activation of those low frequency MUC16-specific T
cells. MUC16 is known to be expressed at low levels, primarily in female reproductive
tissues, such as the fallopian tubes and cervix. We therefore used healthy male donor PBMCs
to try to isolate MUC16-specific T cells, which we reasoned would increase our chances of
68

isolating T cells. Since not every person necessarily possess high-affinity MUC16-specific T
cells, repeating the isolation approach different donors might yield a greater chance of
success. Using PBMCs from a tumor-bearing patient to isolate T cells may also have been a
plausible approach. It is possible that they could possess some TAA-specific T cells that have
been exposed to MUC16 on tumors, but could be suffering from an immunosuppressive
tumor microenvironment. If we could isolate T cells directly from these tumors, we may have
better success at expanding them. Due to the unsuccessful generation of T cells specific for
MUC16, we chose to end our pursuit of this TAA target. We instead began working on the
isolation of T cells against a different TAA, VGLL1, in collaboration with Dr. Cassian Yee’s
laboratory, as described in the next chapter.
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CHAPTER III:
IDENTIFICATION OF THE SHARED CANCER PLACENTA ANTIGEN
VESTIGIAL-LIKE 1 IN PANCREATIC CANCER
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3.1 Rationale for tumor antigen discovery in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC), the most aggressive form of pancreatic
cancer, remains notorious for its poor prognosis and high mortality rate, with its overall 5year survival rate of 8% being amongst the lowest of all cancer types [124, 125]. Early
detection is unusual, with 85% of patients presenting with locally advanced or metastatic
disease [126]. Progress towards effective treatment has been slow and the incidence of
PDAC-related deaths has continued to rise [127],[128]. Despite some encouraging recent
improvements in survival achieved through optimizing the sequencing of surgery and
chemotherapy treatment regimens, developing new and effective therapeutic options remains
a dire need for advanced-stage PDAC patients [129].
Checkpoint inhibitor (CPI) therapies that act through non-specific activation of T
lymphocytes have made a significant positive impact on long-term patient survival [130].
However, the benefits of CPI have mainly been limited to highly mutated tumor types like
melanoma and lung adenocarcinoma that can express a large array of potential neo-antigen
peptides in the context of surface HLA molecules [131],[128]. Tumor-infiltrating lymphocyte
(TIL) therapy, in which individual cancer patients are re-infused with T cells expanded from
their own tumors, has also shown great promise for inducing the regression of bulky
tumors.[132],[133] TIL are polyclonal and can recognize both patient-specific neo-antigens
as well as shared tumor-associated antigens (TAA) such as melanocyte differentiation
antigens (MDA) or cancer-testis antigens (CTA)[134], [135],[136]. Targeting of individual
validated HLA class I-restricted TAAs through infusion of antigen-specific endogenous Tcells (ETC therapy) or genetically engineered TCR-T cells has also proven successful at
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inducing clinical responses in patients with melanoma and other solid cancers [137], [138]
,[139] ,[140] ,[141].
CPI- and CTL-based immunotherapies have unfortunately not shown the same
beneficial impact in treating PDAC patients [142], [143]. This lack of success has been
attributed to the highly immune suppressive tumor microenvironment (TME) of PDAC, in
addition to the relatively low mutational burden that contributes to a dearth of potential neoantigen targets [144], [120], [145], [146]. A number of potentially targetable HLA class I-restricted
peptide antigens have been identified in PDAC, most notably those derived from
carcinoembryonic antigen-related cell adhesion molecule (CEACAM), mucin 16 (MUC16),
mesothelin (MSLN), and mutated KRAS, among others [147], [106], [148], [149], [150].
Although promising, therapies targeting these TAAs have faced inherent limitations,
including the induction of toxicities in non-tumor tissues, low prevalence of target antigen
expression, or inability to break self-tolerance mechanisms that often hinders the generation
of high-affinity CTL [142], [104], [151]. With limited exceptions, clinical trials targeting
these antigens have yielded disappointing results, underscoring the need to identify
immunogenic targets that demonstrate higher prevalence in PDAC patients.
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3.2 Pancreatic cancer MS-based TAA discovery and antigen-specific T cell generation
3.2a.) Immunopeptidome analysis of PDAC patient tumors identifies tumorassociated peptides
To identify peptide targets for CTL-based immunotherapy of PDAC, we analyzed 39
tumor specimens derived from 35 PDAC patients treated at M.D. Anderson Cancer Center.
This included 34 freshly-excised surgical specimens (20 metastatic and 14 primary tumors),
in addition to 3 patient-derived xenografts (PDX) and 2 organoid cell lines derived from
metastases. Tumor cells were lysed and subjected to total HLA class I immunoprecipitation
and acid elution, followed by tandem mass spectrometry (MS) to analyze the HLA-bound
peptides. Eluted peptide fragmentation spectra were searched against the Swiss-Prot database
(updated 9/2018) to identify matches encoded within the human proteome. Individual peptide
matches were assessed using several orthogonal parameters, including Mascot Ion score,
MS1 mass differential (delta mass), and predicted binding to the patient’s HLA allotypes as
determined by high-resolution genetic sequencing [100], [101]. Further validation and
potential suitability as therapeutic TAA targets was determined by evaluating all peptideencoding genes for (1) patient tumor tissue transcript expression as determined by RNAseq,
(2) normal tissue transcript expression (GTex Portal database), and (3) overall expression in
tumor tissues (TCGA database) (Figure 3.3A). (http://www.gtexportal.org/home/,
http://cancergenome.nih.gov/)
The amount of immunoprecipitated HLA class I correlated with the size of the fresh
tumor specimens analyzed (R2 = 0.79), with the exception of 8 tumors (21.6%) that showed
low HLA class I expression as assessed by Western blot analysis (Figure 3.1, Table 3.1). As
expected, HLA class I protein levels also correlated with the number of Swis-Prot database
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matches to eluted peptides (R2 = 0.62, Figure 3.2). Overall, the 39 tumor specimens analyzed
yielded a total of 23,245 unique, high confidence peptide identities, of which 7,966 peptides
(34.3%) were 8- to 13-mer peptides predicted to bind to one or more patient HLA class I
allotypes. Fresh tumor specimens yielded a highly variable number of peptides, ranging from
238 to 1657 (mean = 542). For 3 patients, PDX derivation resulted in larger tumor
specimens, yielding an increased number of eluted peptides in all 3 cases. One of the two
patient-derived organoid cell lines (MP015) yielded the highest number of eluted peptides
overall (n = 1903), underscoring the quantitative advantage provided by expanding tumor
specimens in vitro prior to MS analysis (Table 3.1, Figure. 3.2).
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Quantity of immunoprecipitated HLA class I correlates with PDAC tumor specimen
weight.

Figure 3.1 Quantity of immunoprecipitated HLA class I correlates with PDAC tumor specimen
weight.
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Figure 3.1 Quantity of immunoprecipitated HLA class I correlates with PDAC tumor
specimen weight. Surgical tumor resections from PDAC patients (n=36) or patient-derived
xenografts (n=3) was weighed prior to tissue lysis and immunoprecipitation of total HLA class I
using mAb W6/32. Recovered HLA class I was quantitated based on Western blot analysis by
assessing the HLA class I band intensity (expected size 42 - 44 KD) on a scale of 0 (none detected) to
4 (highest level detected). Graph shows specimen weight plotted by Western blot band intensity; the
dotted line delineates samples with lower than expected HLA class I recovery, indicating reduced
tumor HLA expression.

76

Total number of detected PDAC-associated peptides correlates with quantity
of recovered HLA class I.

Figure 3.2 Total number of detected PDAC-associated peptides correlates with quantity of recovered
HLA class I.
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Figure 3.2 Total number of detected PDAC-associated peptides correlates with quantity
of recovered HLA class I. HLA class I recovered from patient-derived surgical resections (n=36),
xenografts (n=3), or organoid cell lines (n=2) was quantitated by Western blot analysis by assessing
the HLA class I band intensity (size 42 - 44 KD) on a scale of 0 (none detected) to 4 (highest level
detected). Peptides eluted from immunoprecipitated HLA class I were analyzed by tandem MS and
searched against the SwissProt human proteome database. Graph shows number of unique, high
quality peptide matches (Mascot Ion score of 20 or higher) plotted against HLA class I intensity, as
analyzed by Western blot.

78

79

3.2b.) Expression profiling of peptide-encoding genes identifies VGLL1 as a novel
pancreatic cancer TAA
To evaluate if any of the eluted peptides constituted safe therapeutic CTL targets,
peptide-encoding genes were individually assessed for normal tissue transcript expression
with reference to the GTex Portal database containing RNAseq data of 42 different human
tissues. Normal tissues (excluding testis) were categorized into 4 groups that reflected the
potential toxicities expected from off-target killing activity by antigen-specific CTLs (Table
2.2). Peptide-encoding genes were then screened using four corresponding expression filters
of increasing stringency in order to eliminate candidate TAAs most likely to elicit
autoimmune toxicity in the context of CTL therapy (Figure 3.3B). Thus, while TAA
transcript expression up to 30 TPM maximum was allowed in non-essential tissues (such as
prostate, breast, and adipose tissues), a maximum expression threshold of 1 TPM was
imposed for highly essential tissues such as heart and brain, for which CTL recognition can
be lethal.[97], [98]. Using these stringent criteria, 12 TAA peptides were deemed safest to
target, the genes encoding these peptides being MUC16 (encoding 5 unique peptides),
MUC19, ZNF717, EIF5AL1, RGPD1, SLC30A8, MIA2, and VGLL1 (each encoding 1 unique
peptide). Peptides encoded by TAAs MSLN and IDO1 were also detected, but were excluded
in the screening due to elevated RNA transcript expression in normal lung tissue (88 TPM
and 16 TPM, respectively, Figure 3.3B). Amongst the TAAs deemed safest to target, only 2
peptides (derived from MIA2 and VGLL1) were found to be presented by tumors of more
than one PDAC patient (Table 3.1).
The 10-mer peptide LSELETPGKY, uniquely encoded by VGLL1, was eluted from
both PDAC patient-derived organoid cell lines MP015-Org and MP081-Org. This peptide
was predicted to bind with high affinity to HLA-A*0101 (51 nM), and RNAseq analysis
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confirmed high VGLL1 transcript expression in both organoid lines (Table 3.1). Peptide
identity was confirmed by targeted LC-MS, in which a synthetic peptide was analyzed as part
of a mixture with organoid tumor-associated peptides. As shown in Figure 3.3C, the
synthetic isotope-labeled peptide LSELETPGKY generated a highly similar fragmentation
spectra to the native VGLL1 peptide detected from PDAC organoid lines MP015-Org and
MP081-Org, and was also detected at nearly identical LC-MS retention times. Targeted MS
analysis on 2 additional HLA-A*0101-expressing cell lines (PANC10.05 and BXPC3)
demonstrated that the same peptide was also presented by PANC10.05, providing further
evidence that LSELETPGKY might constitute a widely shared TAA (Figure 3.4).
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Immunopeptidome analysis reveals a VGLL1-derived peptide expressed by two PDAC
patient-derived organoid lines.

Figure 3.3. Immunopeptidome analysis reveals a VGLL1-derived peptide expressed by
two PDAC patient-derived organoid lines.
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Immunopeptidome analysis reveals a VGLL1-derived peptide expressed by two PDAC
patient-derived organoid lines.

Figure 3.3. Immunopeptidome analysis reveals a VGLL1-derived peptide expressed by
two PDAC patient-derived organoid lines.
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Figure 3.3. Immunopeptidome analysis reveals a VGLL1-derived peptide expressed by
two PDAC patient-derived organoid lines. (A) Experimental strategy to identify PDAC
tumor-specific, HLA class I-bound peptides from 41 tumor specimens derived from 36 M.D.
Anderson PDAC patients. (B) Bioinformatics screening strategy to identify potentially
targetable TAAs from amongst the eluted PDAC-associated peptides. Peptide-encoding
genes were assessed for PDAC tumor RNAseq expression compared with transcript
expression in 42 GTex Portal normal tissues. Excluding testis, normal tissues were separated
into 4 categories (non-essential, caution, hazard, and danger tissues) that reflected the
potential toxicities expected from off-tumor killing activity against different tissues (Table
2.2). All peptide-encoding genes were filtered successively using four corresponding
expression thresholds of increasing stringency (30, 10, 3, and 1 TPM, indicated by green
dotted lines) to eliminate candidate TAAs most likely to elicit autoimmune toxicity in the
context of CTL therapy (red dotted lines). Screening of high-confidence peptides isolated
from tumor organoid cell lines of PDAC patients MP015 and MP081 is depicted, showing
that only a few eluted peptides met these stringent safety criteria. (C) Mass spectra of an
HLA-A*0101-restricted VGLL1-derived peptide isolated from two different organoid cell
lines, MP015 and MP081 (top 2 panels). The patient-derived peptides co-eluted with and
matched the MS fragmentation spectra of the synthetic isotope-labeled VGLL1 peptide
LSELETPGKY (containing a 13C/15N-labeled lysine residue), with the labeled y+ fragment
ion series demonstrating an expected shift of 8 atomic mass units (bottom panel).
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VGLL1-derived peptide was eluted from the PANC-1005 cell line

Figure 3.4 VGLL1-derived peptide was eluted from the PANC-1005 cell line.
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Figure 3.4 VGLL1-derived peptide was eluted from the PANC-1005 cell line. Mass
spectra of HLA-A*0101-restricted VGLL1-derived peptide isolated from PDAC cell line
PANC-1005 (top panel). This native peptide co-eluted with and matched the MS
fragmentation spectra of the synthetic isotope-labeled peptide LSELETPGKY containing a
13

C/15N-labeled lysine residue (bottom panel).
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3.2c.) VGLL1 is expressed by multiple cancer types and is associated with poorer
overall survival
VGLL1, also known as TONDU, was first identified as the human homolog of the
Vestigial (Vg) protein in Drosophila, a key regulator of wing development [152], [153].
Since VGLL1 is a transcriptional co-activator that binds to the TEA domain family of
transcription factors (TEFs) implicated in cancer development, we further examined VGLL1
transcript expression in the 31 cancer types listed in The Cancer Genome Atlas (TCGA). As
shown in (Figure 3.5A), in comparison to most normal tissues, VGLL1 is overexpressed in a
number of different cancer types, including PDAC, bladder, ovarian, breast, lung, and
stomach cancer. Interestingly, VGLL1 appears to be preferentially expressed in basal-like
breast cancers while demonstrating a relatively low prevalence in other breast cancer
subtypes (Figure 3.6). A similar tumor-associated expression profile was confirmed by
microarray gene expression analysis of tumor cell lines listed in the Cancer Cell Line
Encyclopedia (CCLE, Figure 3.7). According to the GTex RNAseq database, the highest
median VGLL1 transcript expression was found in 3 non-essential tissues: bladder (15.3
TPM), salivary gland (3.9 TPM), and breast (1.3 TPM). The highest level of VGLL1
transcript expression in essential tissues was in normal lung (1.0 TPM), esophagus (0.73
TPM), and kidney (0.34 TPM), while VGLL1 expression in heart and brain tissues was
virtually undetectable (Figure 3.5A). Collectively, this data suggested that VGLL1 may
constitute a safe, targetable TAA for multiple cancer types.
We next assessed if tumor VGLL1 transcript expression was associated with cancer
patient survival. As shown in Figure 2B, TCGA PDAC patient survival (n = 175) was found
to be inversely correlated with VGLL1 expression: patients with high expression had a
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significantly shorter overall median survival compared to patients with low or absent
expression (16 months vs. 37 months, p=0.001). This was confirmed in a independent cohort
of 37 M.D. Anderson PDAC patients for whom PDX tissues could be derived: patients
showing an overall survival of less 18 months demonstrated a significantly higher mean PDX
VGLL1 expression compared to patients that survived longer than 36 months (57.3 TPM vs.
9.6 TPM, p=0.003, Figure 2C). It is worth noting that VGLL1 transcript expression was
found to be considerably higher in PDAC tumor cell lines and PDX tissues compared with
surgically resected PDAC tumors, perhaps due to the high stromal content of many PDAC
tumors in situ (Figures. 3.5A, 3.5C, Table 3.1). Highly elevated VGLL1 expression was also
associated with shorter overall survival time in breast cancer (p = 0.037) and stomach cancer
(p = 0.047), but showed no association with survival in ovarian cancer (Figure 3.8) [154].
Interestingly, low or absent VGLL1 expression was associated with shorter survival time in
bladder cancer (p = 0.036). One possible explanation is that loss a normal bladder tissue
antigen like VGLL1 may indicate tumor dedifferentiation, which has been associated with
poorer prognosis in bladder cancer and other tumor types [155].
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VGLL1 is overexpressed in multiple tumor types and
is associated with reduced pancreatic patient survival

Figure 3.5 VGLL1 is overexpressed in multiple tumor types and is associated with poor
pancreatic patient survival.
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VGLL1 is overexpressed in multiple tumor types and
is associated with reduced pancreatic patient survival

Figure 3.5 VGLL1 is overexpressed in multiple tumor types and is associated with poor
pancreatic patient survival.
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Figure 3.5 VGLL1 is overexpressed in multiple tumor types and is associated with poor
pancreatic patient survival. (A) VGLL1 transcript expression in normal tissues (colored
dots, GTex Portal database) and human cancers (black dots, TCGA database), as determined
by RNAseq analyses. Each dot represents one normal donor or patient tumor sample. Colors
correspond to the 4 normal tissue categories defined in Figure 1: Green, non-essential tissues;
Yellow, caution tissues; Orange, hazard tissues; Red, danger tissues. Although >95% of
analyzed normal GTex caution, hazard, and danger tissue samples fell below 3 transcripts per
million (TPM, dotted line), many TCGA cancer specimens demonstrate VGLL1 expression
well above this threshold. (B) Kaplan-Meier curves showing TCGA PDAC patient overall
survival (OS) stratified by tumor VGLL1 transcript expression (n = 175). P-values indicate
log-rank significance test results comparing the OS of 3 groups of VGLL1-expressing
patients to those patients with low or absent VGLL1 expression. (C) Patient-derived
xenografts (PDX) from an independent cohort of MD Anderson metastatic PDAC patient
tumors (n = 37) underwent RNAseq analysis after being grown in immunodeficient mice.
Stratification of these PDAC patients into 3 groups corresponding to OS time showed that
mean VGLL1 transcript expression was significantly associated with shorter patient survival
time.
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Basal-like subset of Breast Cancer shows elevated VGLL1 Expression

Figure 3.6 VGLL1 is preferentially expressed in basal-like breast cancer compared to other
breast cancer subtypes.
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Figure 3.6 VGLL1 is preferentially expressed in basal-like breast cancer compared to
other breast cancer subtypes. TCGA breast cancer patients were subdivided into 5 major
sub-types (LumA, LumB, Basal-like, HER2 overexpressing, and normal-like) and analyzed
for tumor VGLL1 expression by RNAseq analysis. Each dot represents one TCGA patient
sample, and VGLL1 transcript expression is expressed in fragments per kilobase of transcript
per million mapped reads (FPKM).
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VGLL1 prevalence and expression in CCLE tumor cell lines

Figure 3.7 VGLL1 gene expression in tumor cell lines derived from a variety of cancer types.
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Figure 3.7 VGLL1 gene expression in tumor cell lines derived from a variety of cancer types.
Gene expression microarray analysis of a diverse array of tumor cell lines (n=679) from the Cancer
Cell Line Encyclopedia (CCLE) showed that VGLL1 is expressed by a majority of PDAC and bladder
cancer cell lines, in addition to a significant percentage of breast, gastric, ovarian, and lung cancer cell
lines. No VGLL1 expression was found in cell lines derived from melanoma, thyroid, or hematopoietic
cancers. Threshold for VGLL1 antigen positivity was 3-fold above background signal.
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High tumor VGLL1 expression is associated with reduced survival in stomach
and breast cancers

Figure 3.8 High tumor VGLL1 expression is associated with reduced survival in multiple cancer
types.
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Figure 3.8 High tumor VGLL1 expression is associated with reduced survival in multiple cancer
types. TCGA cancer patients were stratified into three groups according to tumor VGLL1 expression
as determined by RNAseq analysis. Kaplan-Meier curves show overall survival (OS) of each group for
(A) Stomach adenocarcinoma, (B) Breast carcinoma, (C) Ovarian serous adenocarcinoma, and (D)
bladder urothelial carcinoma patients. P-values indicate log-rank significance test results comparing the
OS of the groups with the lowest and highest VGLL1 expression (blue vs. red).
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3.2d.) VGLL1 is part of a unique group of Cancer-Placenta Antigens (CPAs) with
therapeutic potential
VGLL1 had been previously identified as having a regulatory role during early events
in human placental development, and is a specific marker of proliferative cytotrophoblast
[156]. In accordance with this, RNAseq gene expression data from 7 human placenta
samples showed that VGLL1 demonstrates the highest expression in this tissue by a large
margin (mean = 302.7 TPM), nearly 20-fold higher than its expression normal bladder
(Figure 3.9A). This led us to explore the notion that cancer-placenta antigens (CPA) may
constitute a distinct category of targetable TAAs analogous to cancer-testis antigens (CTAs),
which have been successfully targeted with CTL-based therapies. To identify other CPAs
with similar expression profiles to VGLL1, we searched the GTex, TCGA, and other
RNAseq databases for genes that demonstrated the following attributes: (1) highest normal
tissue expression in placenta; (2) low to absent expression in other normal tissues; and (3)
elevated expression in pancreatic, breast, bladder, and/or ovarian cancer. This search yielded
9 additional genes, including Placenta-specific 1 (PLAC1), previously identified as a target of
humoral antitumor immunity in cancer patients[157]. Interestingly, Chorionic Gonadotropin
(CG) Beta subunits 3 and 5 (CGB3/CGB5), components of the CG hormone complex
produced by placental trophoblasts during pregnancy, were also identified as potential CPAs
due to their overexpression in a subset of pancreatic, testicular, uterine, and bladder cancers
(Figure 3.10B). The other 6 putative CPAs demonstrated diverse expression profiles, ranging
from those found only in a restricted set of cancer types (IGF2BP3, ADAM12), to those
overexpressed in most cancer types but also demonstrating elevated expression in normal
female reproductive tissues (CAPN6, MMP11) (Figure 3.9, Figure 3.10.). Although we did
not detect peptides derived from these genes in this set of PDAC specimens, epitopes from
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several of these putative CPAs have been identified in multiple tumor types and are listed in
the Immune Epitope Database (IEDB) [157].
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VGLL1 is a cancer-placenta antigen (CPA) demonstrating high expression in
placenta and tumors

Figure 3.9 VGLL1 is a cancer-placenta antigen (CPA) demonstrating high expression in normal
placenta and tumors.
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Figure 3.9 VGLL1 is a cancer-placenta antigen (CPA) demonstrating high expression in
normal placenta and tumors. Gene expression profiling uncovered 9 additional putative
CPAs with similar expression profiles to VGLL1. (A) Heatmap depicting the mean transcript
expression of different CPAs in normal placenta (top), GTex normal tissues, and transformed
lymphocytes and fibroblasts (bottom). Tissues are listed in order of highest to lowest VGLL1
expression, as determined by RNAseq analysis. (B) Heatmaps displaying the mean CPA
transcript expression (left) and frequency (right) of CPA-positive tumor specimens in 34
different TCGA cancer types as determined by RNAseq. CPA-positive specimens were
defined as having tumor CPA transcript expression >5 TPM. Tumor tissues are listed in order
of highest to lowest VGLL1 prevalence.
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Mean expression of cancer-placenta antigens in all TCGA tumor specimens

Figure 3.10 Expression of cancer-placenta antigens (CPAs) in all TCGA tumor
specimens.
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Figure 3.10 Expression of cancer-placenta antigens (CPAs) in all TCGA tumor
specimens. Gene expression profiling to search for potential TAAs with similar expression
profiles to VGLL1 uncovered nine additional putative CPAs. Heatmap depicts the mean
transcript expression of all 10 CPAs in 34 different TCGA cancer types, as determined by
RNAseq. Tumor tissues are listed in order of highest to lowest mean VGLL1 transcript
expression.

103

3.3 Generation and validation of VGLL1-specific T cells
3.3a.) VGLL1-specific cytotoxic T cells were expanded from the peripheral blood of PDAC
patient MP015

Patient MP015 was a previously healthy 50-year old male first diagnosed with
primary PDAC in December 2011. Two years following surgical removal of the primary
pancreatic tumor, a thorascopic wedge resection of a left lung lesion was performed in
November 2013 and used to derive organoid cell line MP015-Org [158]. The disease was
kept in check for nearly 2 more years through a series of chemotherapeutic regimens, but
following progression he was enrolled in an IRB-approved cell therapy protocol at M.D.
Anderson to receive autologous, expanded tumor-antigen-specific CTLs. Immunopeptidome
analysis performed on the expanded organoid cell line MP015-Org in May 2015 led to the
identification of 6 HLA class I-bound peptides (4 derived from MUC16 and 1 each from
ZNF717 and VGLL1) that met our criteria as safe, targetable TAAs (Table 2.3). Custom
clinical-grade tetramers were available for 3 of the 6 potential targets: two HLA-B*3502restricted MUC16 peptides and the single HLA-A*0101-restricted VGLL1 peptide.
Following leukapheresis, patient MP015 PBMCs were stimulated twice with
individual peptide-pulsed DCs in the presence of IL-21, followed by tetramer-based sorting
of antigen-specific CD8+ T cells (Figure 3.11A). Although MUC16-specific CTLs failed to
expand from patient PBMC, VGLL1 CTLs expanded successfully, with VGLL1 tetramerpositive T cells comprising 3.4% of CD8+ after 2 weeks of DC-peptide stimulation (Figure.
3.11B). Cell sorting followed by employment of the rapid expansion protocol (REP) was
repeated twice, resulting in nearly 20 billion expanded CTLs, of which >90% were VGLL1
tetramer-positive and demonstrated restricted Vβ usage (Figure 3.11B and C). VGLL1-
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specific CTLs were also successfully expanded from 2 of 2 healthy HLA-A*0101-positive
blood donors, demonstrating the general immunogenicity of the LSELETPGKY peptide
(Figure 3.12).
Expanded CTLs from patient MP015 were tested functionally using standard 51Cr
release assays. Mel888 melanoma cells (VGLL1-negative, HLA-A*0101 positive) pulsed
with titrated amounts of VGLL1 peptide elicited CTL recognition and killing at peptide
concentrations as low as 10 nM, indicating relatively high affinity for cognate peptide
(Figure 3.11D). Importantly, expanded patient-derived CTLs also showed robust recognition
of the autologous organoid cell line MP015-Org from which the VGLL1 peptide was
originally detected by MS (Figure 3.11A). In October 2015 following a pre-treatment
regimen of Cytoxan, Patient MP015 was infused with 19.6 billion autologous, expanded
VGLL1-specific CTL, subsequently receiving interleukin-2 and pembrolizumab. Although
the patient experienced a transient fever (a frequent side effect of T-cell infusion-induced
cytokine release), they experienced no adverse events indicating potential CTL-mediated
toxicities. Unfortunately, scans in late November 2015 showed rapid disease progression
manifested as an interval increase in lung lesions and pleural-based metastatic disease [158].
Surprisingly, biopsy of a pleural-based nodule at this time revealed a poorly differentiated
neuroendocrine tumor. DNA sequencing analysis of serial liquid biopsies collected over the
previous 18 months provided evidence of an extremely rapid evolution of Patient MP015’s
cancer due to numerous progressive genetic amplifications, deletions, re-arrangements, and
epigenetic changes. RNAseq analysis also demonstrated that a dramatic reduction in VGLL1
transcript expression (35.1 TPM to 1.6 TPM) had occurred between December 2013 and
December 2015, providing a potential explanation for the lack of clinical response to ETC
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therapy (Figure 3.14). Patient MP015 expired in January 2016 due to extensive
complications deriving from progression of his lung metastases [158].
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Mean expression of cancer-placenta antigens in all TCGA tumor specimens

Figure 3.11. Generation of VGLL1 antigen-specific CTLs from peripheral blood of Patient
MP015.
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Figure 3.11. Generation of VGLL1 antigen-specific CTLs from peripheral blood of
Patient MP015.
(A) Schematic outlining the experimental procedure for generating VGLL1-specific CD8+ Tcells from human donor PBMCs. (B) PBMC isolated from PDAC Patient MP015 by
leukapheresis were stimulated with autologous LSELETPGKY peptide-pulsed dendritic cells
(DCs). After two stimulations (top row), CD8+ and VGLL1 tetramer-positive cells were
sorted and expanded using a standard rapid expansion protocol (REP). VGLL1-specific Tcells were re-sorted and expanded a second time due to low numbers of antigen-specific cells
following the first REP. The second REP yielded 19.6 x 109 VGLL1-specific CTLs, which
Patient MP015 safely received as an infusion under a personalized ETC therapy
Compassionate IND protocol. TCR repertoire analysis of expanded VGLL1-specific CTLs
was also performed using Vβ antibodies corresponding to 24 different specificities (bottom
panels). (C) VGLL1-specific T-cells expanded from Patient MP015 were tested for
functionality in a standard 51Cr release assay to assess specific lysis of Mel888 melanoma
tumor cells (VGLL1-negative HLA-A*0101-positive) pulsed with titrated amounts of
LSELETPGKY peptide at a 5:1 effector-to-target (E:T) ratio.
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VGLL1-specific CTLs were expanded from PBMC of multiple donors

Figure 3.12 Generation of HLA-A*0101-restricted VGLL1 antigen-specific CTLs from multiple normal
donor PBMC.
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VGLL1-specific CTLs were expanded from PBMC of multiple donors

Figure 3.12 Generation of HLA-A*0101-restricted VGLL1 antigen-specific CTLs from multiple normal
donor PBMC.
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Figure 3.12. Generation of HLA-A*0101-restricted VGLL1 antigen-specific CTLs from
multiple normal donor PBMC. (A and B) Induction of VGLL1-specific CD8 T cells from PBMC
of two healthy donors. HLA A*0101-expressing donor PBMC were stimulated with LSELETPGKY
peptide-pulsed dendritic cells for 2 weeks. VGLL1 tetramer-positive CD8 T cells were sorted by
ARIA sorter after 2 stimulations (top panels) and the sorted T cells were expanded using a standard
rapid expansion protocol (REP). TCR repertoire analysis of expanded VGLL1-specific CTLs was
performed using Vβ antibodies corresponding to 24 different specificities (bottom panels).
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RNAseq analysis of lung tumor biopsies revealed loss of VGLL1 expression in
PDAC Patient MP015

Figure 3.13 PDAC patient MP015 showed loss of VGLL1 antigen expression prior to VGLL1CTL therapy.
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Figure 3.13. PDAC patient MP015 showed loss of VGLL1 antigen expression prior to VGLL1CTL therapy. Serial liquid biopsies were acquired from the lung metastases of PDAC Patient
MP015 at different time points during treatment at M.D. Anderson. Retrospective longitudinal
RNAseq analyses of these samples revealed that VGLL1 transcript expression was lost in the months
prior to receiving VGLL1-specific ETC therapy.
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3.3b.) VGLL1-CTLs demonstrate cytotoxicity against multiple allogeneic PDAC tumor cell
lines.

Although Patient MP015 did not experience clinical benefit from adoptive transfer of
his own VGLL1-specific CTLs, the robust antitumor activity demonstrated by these T-cells
in vitro led us to explore whether they may possibly benefit other PDAC patients. HLAA*0101 was expressed by ~30% of our PDAC patient cohort, and RNAseq analysis of
TCGA and MDACC PDAC surgical specimens and PDXs showed that 43.2% to 62.5% of
patients express VGLL1 transcript at a level > 5 TPM. From these data, we estimate that 12%
to 15% of PDAC patients present the LSELETPGKY peptide target in the context of HLAA*0101 and therefore could potentially benefit from VGLL1-CTL therapy.
To determine if VGLL1-CTLs derived from Patient MP015 could recognize
allogeneic PDAC tumors, we tested a panel of HLA-A*0101 expressing PDAC tumor cell
lines as targets for killing using a 51Cr release assay. Western blot analysis was used to
confirm VGLL1 protein expression, and flow cytometry confirmed surface expression of
HLA-A*0101 in cell lines (Figure 3.15). While control cell line WM793 (VGLL1-negative,
HLA-A*0101-positive) was not recognized, VGLL1-specific CTLs recognized autologous
MP015-Org cells and 4 out of 4 allogenic PDAC lines tested, including inducing robust
killing of PANC-1005, CAPAN-1, and BXPC3 (Figures 3.14A and B).
The PDAC organoid cells derived from Patient MP081 were also lysed by VGLL1CTLs but with reduced efficiency, likely due to an outgrowth of VGLL1-negative cells
within the culture (not shown). VGLL1-CTL specificity was demonstrated by co-incubation
with the pan-MHC class I antibody W6/32, which resulted in blockade of PANC10.05
recognition and lysis (Figure 3.16). Collectively, these results provide evidence that the
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LSELETPGKY peptide constitutes a shared PDAC tumor antigen that can be effectively
targeted with VGLL1-specific CTLs.
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RNAseq analysis of lung tumor biopsies revealed loss of VGLL1 expression in
PDAC Patient MP015

Figure 3.14. VGLL1-specific CTLs recognize and kill multiple allogeneic pancreatic
cancer cell lines.
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Figure 3.14. VGLL1-specific CTLs recognize and kill multiple allogeneic pancreatic
cancer cell lines. (A) Expanded VGLL1-specific CD8+ T cells from Patient MP015 were cocultured with a panel of HLA-A*0101-positive PDAC tumor cell lines in a standard 51Cr
release assay to measure cytotoxic activity at different effector-to-target (E:T) cell ratios.
WM793 melanoma cells (VGLL1-negative HLA-A*0101-positive) were used as a negative
control line. VGLL1-CTLs robustly killed the autologous organoid cell line MP015 from
which the VGLL1 peptide was originally isolated, and also demonstrated cytotoxic activity
against four allogeneic, HLA-A*0101-expressing PDAC cell lines. Results show the means
and standard deviations of six replicate samples, and data is representative of a minimum of 4
replicate experiments. (B) Western blot analysis confirmed expression of VGLL1 protein in
all five PDAC cell lines tested.
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HLA-A*0101 surface expression on tumor cells and primary cell lines

Figure 3.15. HLA-A*0101 surface expression confirmed on target cell lines by flow
cytometry.
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Figure 3.15. HLA-A*0101 surface expression confirmed on target cell lines by flow
cytometry. All tumor cell lines and normal primary cells used in this study were stained with
fluorophore-labeled HLA-A*0101-specific mAb and analyzed by flow cytometry to confirm
natural endogenous HLA-A*0101 surface expression (grey histograms) prior to use as targets
in VGLL1-specific CTL assays. Five tumor cell lines were transduced to express HLAA*0101 using a lentiviral expression vector (red histograms).
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HLA Class I Blockade abrogates VGLL1-CTL recognition of PDAC cell line
PANC10.05

Figure 3.16. VGLL1-CTL killing is blocked with an HLA-class I-specific antibody.
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Figure 3.16. VGLL1-CTL killing is blocked with an HLA-class I-specific antibody.
Expanded VGLL1-specific CD8+ T cells were co-cultured with HLA-A*0101-positive
PDAC tumor cell line PNAC-1005 in a standard 51Cr release assay to measure cytotoxic
activity at different effector-to-target (E:T) cell ratios. Addition of the HLA class I blocking
antibody W6/32 largely abrogates VGLL1-CTL killing, demonstrating that antitumor activity
is HLA class I-restricted.
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3.3.c) VGLL1-CTLs show activity against multiple tumor types and reduced recognition of
primary cells

TCGA patient RNAseq data analysis indicated that VGLL1 is expressed by several
cancer types (16 of 31), most notably in 75 - 80% of patients with bladder, ovarian, and
basal-type breast cancers, and 15 - 20% of patients with lung and gastric cancers (Figure
3.4). We therefore set out to determine whether cell lines derived from these cancer types
could be targets for VGLL1-specific CTLs (Figure 3.17A). Western blot analysis of a panel
of ovarian, basal-type breast, bladder, gastric, and lung cancer cell lines showed high VGLL1
expression in 12 of 14 lines analyzed (Figure 3.17B). Of the 8 cell lines that naturally
expressed HLA-A*0101, VGLL1-CTLs killed 2 of 3 ovarian lines, 2 of 3 breast lines, and 2
of 2 bladder and lung cancer lines (Figure 3.17A). Five additional HLA-A*0101-negative
cell lines (2 gastric, 2 bladder, and 1 lung line) were transduced to express HLA-A*0101
prior to testing them as targets for VGLL1-CTLs. As shown in Figure 6A, all five HLAA*0101-transduced cell lines were rendered susceptible to killing by VGLL1-CTLs,
indicating presentation of the LSELETPGKY peptide from processed, endogenouslyexpressed VGLL1 protein. Taken together, these results suggest that VGLL1-CTLs have
potential therapeutic value for at least five additional cancer types besides PDAC.
To assess the safety of VGLL1-CTLs for potential therapeutic use, we tested them
against a panel of normal primary cells most likely to elicit VGLL1-specific reactivity
according to the GTex normal tissue expression profile. Since bladder demonstrated the
highest normal tissue VGLL1 transcript expression, we tested two different HLA-A*0101
positive primary bladder cell lines as targets for VGLL1-CTL killing. As shown in Figure
13.8C, specific lysis was very low, detectable in one bladder line but only at the highest E:T
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ratio. The GTex database indicated that VGLL1 transcript is also expressed at low levels in
normal breast and lung (Figure. 3.3A). We therefore tested VGLL1-CTL killing activity
against HLA-A*0101-expressing primary mammary and lung airway cells, along with
primary melanocytes as a negative control. Of this panel, mammary cells elicited moderately
high levels of killing by VGLL1-specific CTL, results that were consistent with VGLL1
levels as assessed by Western blot (Figure 3.17D). By contrast, lung airway epithelial cells
were not killed by VGLL1-CTLs, despite demonstrating ample HLA-A*0101 surface
expression (Figure 3.15). These results provide supporting evidence that VGLL1-specific T
cells are unlikely to recognize any essential normal tissues; however, safety concerns may be
warranted due to the potential for reactivity against some non-essential tissues.
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VGLL1-CTLs kill cell lines derived from multiple cancers but show reduced
recognition of normal primary cell lines

Figure 3.17 VGLL1-specific T cells recognize and kill multiple tumor types, but have
reduced recognition of primary tissue cell lines.
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VGLL1-CTLs kill cell lines derived from multiple cancers but show reduced
recognition of normal primary cell lines

Figure 3.17 VGLL1-specific T cells recognize and kill multiple tumor types, but have
reduced recognition of primary tissue cell lines.
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Figure 3.17. VGLL1-specific T cells recognize and kill multiple tumor types, but have
reduced recognition of primary tissue cell lines. (A) VGLL1-specific CD8+ T cells were
co-cultured with 12 different HLA-A*0101-expressing tumor cell lines derived from ovarian,
lung, breast, bladder, or gastric cancer in a standard 51Cr release assay to measure cytotoxic
activity at different effector-to-target (E:T) cell ratios. Five HLA-A*0101-negative cell lines
(EBC1, HT1197, HT1376, GT-5, and MKN74) were lentivirally transduced to stably express
HLA-A*0101; VGLL1-CTL killing of the parental cell lines (grey lines) are shown in
comparison to HLA-A*0101-transduced counterparts (black lines). (B) Western blot analysis
confirmed VGLL1 protein expression in 11 of 12 tumor cell lines derived from ovarian, lung,
breast, bladder or gastric cancer. (C) VGLL1-specific CTLs were co-cultured with HLAA*0101-expressing primary tissue cells derived from bladder, breast, kidney, lung airway, or
skin melanocytes in a standard 51Cr release assay to measure cytotoxic activity. VGLL1-CTL
assay results show the means and standard deviations of six replicate samples, and data is
representative of a minimum of 2 replicate experiments. (D) VGLL1 protein expression in
primary cell lines, as accessed by Western blot analysis.
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3.3d.) Discussion
The benefits of immunotherapy have been slow to translate to PDAC, likely due to
the relatively low mutational burden, highly suppressive tumor microenvironment, and a lack
of known TAA targets for CTL therapies [159], [151]. Oncogenic driver mutations in KRAS
represent particularly promising target epitopes due to their tumor specificity and high
prevalence in PDAC, colorectal cancer (CRC), and lung cancer. In an exciting recent case
study, CTLs expanded from TIL of a CRC patient specifically recognized an HLA-C*0802restricted KRAS peptide containing the G12D mutation; furthermore, these TIL were shown
to mediate an objective tumor regression of multiple lung metastases in the patient following
infusion [147]. While highly promising, the low worldwide prevalence of HLA-C*0802
predicts that only ~1.5% of PDAC patients could benefit from targeting this mutated epitope.
TCRs recognizing mutated KRAS epitopes restricted to HLA-A*1101 have also been
reported; although not yet tested in clinical trials, the relatively high prevalence of A*1101
predicts a significantly larger potential patient population that would be centered largely in
Asia [160]. The lack of shared mutations beyond KRAS suggests that identification and
targeting of non-mutated TAAs may represent the most promising opportunity for advancing
immunotherapies for PDAC. Two well-studied TAAs for PDAC and ovarian cancer, MUC16
and MSLN, illustrate the two principal challenges of targeting non-mutated TAAs: difficulty
in breaking T-cell tolerance and, conversely, the potential for induction of on-target offtumor toxicities. Based on low overall normal tissue and relatively high tumor expression,
MUC16 appears to be an ideal TAA; however, isolating high affinity CTLs that recognize
non-mutated MUC16 epitopes has proven elusive [120], [121]. This lack of immunogenicity
may be attributed to tolerogenic attributes of MUC16: being detectable at low levels in
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healthy patient serum, and also being a very large protein (>22,000 AA) containing >50
extracellular tandem repeat domains [122].
Employing an unbiased immunopeptidome analysis of tumor specimens derived from
35 PDAC patients, VGLL1 was identified as a novel putative shared TAA, ranked second
only to MUC16 in terms of tumor overexpression in comparison to essential normal tissues.
However, in contrast to MUC16 epitopes, the HLA-A*0101 restricted VGLL1 peptide was
considerably more immunogenic, capable of eliciting antigen-specific CTLs from multiple
PBMC donors, including one PDAC patient. Such immunogenicity provides a significant
advantage in the context of developing endogenous T-cell (ETC) therapies for cancer
patients. HLA-A*0101 is expressed at a relatively high prevalence (25 to 30%) in Western
European and North American countries, suggesting that these patient populations would be
most likely to benefit from targeting this epitope [161]. Expanded VGLL1-specific CTLs not
only recognized and killed a panel of allogenic PDAC tumor lines, but also demonstrated
reactivity against A*0101-expressing tumor cells derived from five other cancer types. We
estimate that targeting this single VGLL1 epitope could potentially benefit a large number of
Western cancer patients, including over 20% of patients with ovarian, bladder, or basal-like
breast cancers, ~12% of patients with PDAC, and 5 - 10% of patients with lung, stomach,
cervical, uterine, or head and neck cancers.
Higher VGLL1 expression has been associated with shorter patient survival in
multiple cancer types, including triple-negative breast and endometrial cancers [154], [162].
However, its negative impact on survival is most striking in PDAC (Figures 3.5 and 3.6),
suggesting that VGLL1 may play a role in driving tumor aggressiveness. VGLL1 is a co-
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transcriptional activator and a marker of proliferating cytotrophoblasts during early human
placental development where it is co-expressed with the transcription factor TEAD4 [156], [163].
The discovery of VGLL1 prompted us to search for other putative CPAs that
demonstrated overexpression in placenta and tumors, and thus may constitute potential TAA
targets. This search uncovered Placenta-specific 1 (PLAC1), initially identified as a target of
autologous humoral immunity in gastric cancer and hepatocellular carcinoma patients, and
the first CPA reported to represent a class of TAAs distinct from CTAs and oncofetal
antigens [164], [165]. A TCR recognizing an HLA-A*0201-restricted peptide derived from
PLAC1 was recently isolated and shown to possess antitumor activity against human breast
cancer cells in pre-clinical models, but have not yet been tested in clinical trials [166]. As
shown in Figure 3, PLAC1 shows low normal tissue expression, but also demonstrates low
overall prevalence in cancer. By contrast, Insulin-Like Growth Factor 2 mRNA Binding
Protein 3 (IGF2BP3) was also identified as a promising CPA in our screen, showing
relatively high prevalence of expression in ~15 different cancer types, including
glioblastoma, uterine, testicular, and lung cancers (Figure 3.7). The high level of IGF2BP3
expression in normal testis, transformed lymphocytes and transformed fibroblasts suggests
that this protein may also play a role in driving cancer progression, consistent with its
identification as a poor prognostic factor [167], [168]. Unfortunately, IGF2BP3 shows a
significant degree of amino acid identity with IGF2BP2, which is expressed at elevated levels
in several essential normal tissues, thus limiting the number of safely targetable epitopes. Of
the 10 putative CPAs identified, matrix metallopeptidase 11 (MMP11) showed the most
striking expression and prevalence, being expressed at high transcript levels in 25 different
cancer types (Figure 3.8). However, in addition to normal placenta, MMP11 is also

129

expressed at relatively high levels in uterus, cervix, and ovary, suggesting that CTL-based
targeting of MMP11 epitopes may result in reproductive toxicities for women.
In terms of safety profile, cancer prevalence, and immunogenicity, VGLL1 compares
favorably with other known TAA targets. Moreover, one male PDAC patient treated with
autologous, high-affinity VGLL1-specific CTLs experienced no apparent autoimmune
toxicities, providing evidence that VGLL1 can be safely targeted in vivo. However, in vitro
testing did show significant VGLL1-CTL reactivity against cultured primary mammary cells,
suggesting that gender-specific safety considerations should be taken into account when
targeting CPAs. Immediate clinical applications of these findings include a planned clinical
trial to treat HLA-A*0101+/VGLL1+ PDAC patients with VGLL1-specific ETC therapy,
with future cohorts to potentially include bladder, ovarian, and/or breast cancer patients.
VGLL1-specific TCRs derived from Patient MP015 have been cloned and are currently
undergoing validation for future potential clinical applications, including TCR-T cell
therapies. MS-based identification of additional VGLL1 epitopes restricted to other HLA
allotypes is also ongoing, with the promise of expanding the number of treatment-eligible
cancer patients [79]. Although single antigen-based CTL targeting can demonstrate limited
clinical utility due to selection of antigen-loss variants, tumor debulking and subsequent
epitope spreading constitute important aspects of immunotherapeutic success, processes that
may be further augmented when combined with other modalities such as checkpoint
blockade [137],[138]. Collectively, our study shows that VGLL1 is a promising TAA target
that can be used in immune-based therapies to address a clear unmet need in patients with
PDAC and multiple other cancers.
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CHAPTER IV:

CHARACTERIZING THE ROLE OF VGLL1 IN CANCER PROGRESSION
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4.1.) VGLL1 is an important regulator of placental growth during embryo development
and is associated with poor prognosis for pancreatic cancer patients.
Through examining the immunopeptidome of pancreatic cancer, we identified
VGLL1, as a novel cancer placenta antigen shared by multiple cancer types. However, the
role of VGLL1 in cancer progression remains to be elucidated. In total, there are only 15
peer-reviewed publications on VGLL1, and only a subset of these address the role of VGLL1
in cancer. However, we can gleam some insights into its role from studies on primary tissues,
since tumors often “hijack” normal functions of cells to benefit their growth and survival. In
other words, by studying the role of VGLL1 in primary tissues, we may be able to infer what
role it could play in cancer progression.
As previously discussed in chapter 3, VGLL1 is a co-transcriptional activator and an
important regulator of the proliferation of cytotrophoblasts during early human placental
development. VGLL1 is co-expressed with the transcription factor TEAD4 in the hippo
pathway [156], [163]. The hippo-signaling pathway controls organ size, tissue hemostasis,
and regeneration [169]. The Human Protein Atlas (http://www.proteinatlas.org ) contains
IHC staining of placenta tissues, in which VGLL1 is most highly expressed (>200TPM),
mostly in the leading edge of the tissues (Figure 4.1). The outer edge of the placenta is
where cytotrophoblasts are found. Cytotrophoblasts are both highly proliferative and
extremely invasive. There are two forms of villous cytotrophoblast stem cells [170]. One
form of cytotrophoblasts are the cells responsible for invading the mother’s tissue to help the
placenta implant into the uterus [171]. The other form of trophoblasts spread to the arteries of
the mother and bore into the vessels to create the blood flow connection between the mother
and fetus during pregnancy [172].

132

Due to the known invasive VGLL1-expressing cytotrophoblasts, the expression of
VGLL1 in tumor cells may and contribute to the aggressiveness of cancer. As shown in
chapter 3, pancreatic cancer patients with elevated levels of VGLL1 had the shortest overall
survival (Figure 3.5). Additionally, the most aggressive breast cancer subtype, basal-like
breast cancer, possesses the highest expression of VGLL1 out of all breast cancer types
(Figure 3.6).
These two cancers are highly metastatic, and known to spread quickly to neighboring
tissues [173]. Suggesting that VGLL1 expression may play a role in tumor metastasis.
Furthermore, there appears to be a strong homology VGLL1 with the well established
oncogenes YAP and TAZ within in the hippo pathway. In the next section, we will explore
how the oncogenes YAP/TAZ may provide a blueprint to understand the role of VGLL1 in
cancer progression.
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Cytothrophoblasts express VGLL1 in placenta tissue

Figure 4.1 IHC staining of placenta tissue from the Human Protein
Atlas database.
https://www.proteinatlas.org/ENSG00000102243-VGLL1/tissue/placenta#img
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Figure 4.1 IHC staining of placenta tissue from the Human Protein Atlas. VGLL1 is
expressed in the outer edge of the cells in placenta tissue by IHC staining. These VGLL1positive cells are cytothrophoblasts.
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4.2.) VGLL1 shares similar binding motif to TEADs with the oncogenes YAP/TAZ in
the hippo pathway.
The Hippo signaling pathway is a highly conserved intracellular-signaling network
that regulates cell proliferation, organ size, and regeneration [169]. The Hippo signaling
pathway is co-opted in multiple cancers to drive tumor progression [174], [175]. Two wellcharacterized oncogenes, YAP1 (Yes associated protein 1) and TAZ/WWTR1 (WW Domain
Containing Transcription Regulator 1), function as co-transcriptional activators of the Hippo
signaling pathway, and in cancers they, also bind to TEAD proteins, leading to the
upregulation of several cancer-promoting genes (Figure 4.3) [152], [176], [177]. It is
important to note that YAP and TAZ are two distinct proteins, but are often referenced
together because they share mostly redundant functions within the Hippo signaling pathway
[178].
YAP is over-expressed in pancreatic cancer and has been linked to promoting factors
such as tumorigenesis and chemoresistance (Figure 4.2). YAP has also been shown to
promote EMT transition in pancreatic cancer, increasing cell motility, invasion, and
tumorigenesis through hyperactivation of AKT signaling [176, 179, 180]. Additionally,
YAP/TAZ were identified as partners to mutant KRAS in pancreatic cancer [169]. In vivo
experimental models show that YAP/TAZ act as transcriptional activators downstream of
KRAS, resulting in the upregulation of genes that promote proliferation and invasiveness
[181]. These two genes have been well characterized in multiple cancers as also being
associated with pro-inflammatory responses, migration, and immune evasion [182-184]. The
interaction of YAP/TAZ with TEADs was shown to induce PD-L1 upregulation and
inhibited T cell function when overexpressed in breast epithelial cells [185].
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Oncogenes YAP/TAZ role in the Hippo signaling pathway in pancreatic cancer

Figure 4.2 The Hippo signal pathway in pancreatic cancer.

Figure used with premission from author:
Ansari D, Ohlsson H, Althini C, Bauden M, Zhou Q, Hu D, Andersson R: The Hippo Signaling
Pathway in Pancreatic Cancer. Anticancer Res 2019, 39(7):3317-3321.
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Figure 4.2 The Hippo signal pathway in pancreatic cancer. Upstream signaling in the
hippo pathway results in the phosphorylation of YAP, and its co-activator (TAZ). When
YAP and TAZ are held in the cytoplasm, they are degraded to prevent their entry into the
nucleus. In the nucleus, they bind to TEADs 1-4, and are responsible for the upregulation of
genes involved in proliferation. However, aberrant signaling of the hippo pathway in
pancreatic cancer is associated with cancer promoting factors.
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VGLL1 has been shown to interact with TEAD4 in a manner similar to that of
YAP/TAZ, resulting in the upregulation of the proliferation-promoting gene IGFBP5 and
facilitating anchorage-independent cell growth (Figure 4.3) [163]. These studies suggest that
VGLL1 may promote cancer progression directly, which would increase its potential value as
a therapeutic target. Although the VGLL1 transcript loss observed in Patient MP015 could
argue against a role as an essential driver gene, the degree of tumor evolution documented in
this patient’s cancer progression was exceptionally high [158].
The function of VGLL1 in healthy tissues, points to a critical role in placenta cell
proliferation. In addition, (Figure 3.5), high VGLL1 expression in pancreatic and basal-like
breast cancer patients is associated with a poorer prognosis [154]. Furthermore, cancer cells
are known to co-opt the Hippo signaling pathway and upregulate YAP/TAZ to increase
tumor- promoting factors. Based on the current evidence on YAP/TAZ within the Hippo
signaling pathway and the connection with VGLL1, we hypothesized that VGLL1 may play
a role in cancer tumorigenesis through promoting proliferation, migration, and/or invasion. In
the following section, we will discuss how we aimed to test our hypothesis and demonstrate
why VGLL1 is a promising therapeutic target in pancreatic cancer.
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VGLL1 shares similar interaction with TEADs as the oncogenes YAP/TAZ

Figure 4.3 VGLL1 and YAP/TAZ share similar interaction with TEADs in the hippo
pathway.

Figure used with premission from author:
Pobbati AV, Chan SW, Lee I, Song H, Hong W: Structural and functional similarity between the
Vgll1-TEAD and the YAP-TEAD complexes. Structure 2012, 20(7):1135-1140.
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Figure 4.3 VGLL1 and YAP/TAZ share similar interaction with TEADs in the hippo
pathway. The well-established YAP/TAZ oncogenes bind to TEADs in cancer cells to
activate cancer-promoting factors. VGLL1 appears to also bind to the TEADs and perform a
similar function, by upregulating genes that are also known to promote cancer progression
such as; VEGF-A and the anchorage-independent growth factor IGFBP-5.
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4.3.) VGLL1 overexpression leads to increased proliferation, migration, and invasion of
cancer cells in vitro.
To access any potential changes that VGLL1 expression may induce in tumors, we
first generated two VGLL1-overexpressing lines. VGLL1 lenti-viral vectors were used to
transduce tumor cells that did not express VGLL1, as assessed by western blot. We utilized
the cell lines PANC1, a pancreatic tumor cell line, and H1975, a lung cancer line. The cells
were transduced to express VGLL1, and VGLL1 protein expression was validated by
Western blot analysis, as shown in Figure 4.4A. PANC10.05, a naturally-expressing
VGLL1-postive cell line was used as a positive control. We next generated transient
knockdowns of the VGLL1 transduced H1975 lung cancer cells. To create the transient
knockdowns, we used esiRNA vectors (MISSION® esiRNA Cat. #EHU042561); this
allowed for increased chances of knocking down VGLL1 expression to a greater degree than
standard siRNA. Mission esiRNA works by targeting the same mRNA sequence with
multiple siRNAs, and thus guarantees at least a 70% knockdown efficiency. We confirmed
reduced VGLL1 expression in the knockdown cells by Western blot analysis (Figure 4.4B).
Following the validation of the VGLL1- transduced cell lines, we proceeded to
observe morphological changes in the cells. Evident growth and phenotypic differences were
found in the H1975 cell lines post-VGLL1 transduction. Cells were plated and analyzed
using microcopy at 24, 48, 72, and 96 hours. As shown in Figure 4.5 at the 72hr mark,
VGLL1 over-expressing H1975 lung tumor cells had formed multiple clusters despite
growing in a 2D culture (Figure 4.5C). The clusters resembled similar growth patterns to 3D
spherical organoid cell culture, similar to the MP015 organoid cell line from which the
VGLL1 peptide was derived.
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This may indicate ability of VGLL1 to induce growth in an anchorage-independent
matter [186, 187], which is also an indication of metastatic potential [186]. The colonies
were alive; some were attached to the flask and some were floating in the supernatant.
However, once they were collected and re-plated, all cells survived and continued to grow
and expand in a similar matter. Knocking down VGLL1 in the overexpressed lung cancer
cells returned the cells to a similar phenotype of parental H1975 cells and GFP-transduced
control cells (Figure 4.5D).
Simultaneously we counted the H1975 tumor cells to assess proliferation counts. On
day one, we plated 30,000 cells in triplicates, and the cells were observed at 24, 48, 72, and
96hr mark, using a Nexcelom cellometer (Figure 4.6). As expected, the VGLL1
overexpressed cells proliferated faster than the WT VGLL1-negative cells, P >0.001 (Figure
4.6). Additionally, the VGLL1 knockdown cells grew similarly to the parental line (Figure
4.6). We failed to reject our hypothesis that VGLL1 plays a role in tumor cell proliferation.
The upregulation of VGLL1 may be used by tumor cells to promote growth.
The few papers that have been published on VGLL1 hint at its potential role in tumor
cell migration and invasion. Migration and invasion differ from one another, in that
migration refers only to a cell’s ability to fill-in an area or move from one point to another
[188]. Invasion defers from migration; in that it looks at the ability to migrate coupled with
the cell’s ability to move past an extracellular matrix. We first accessed the ability of PANC1
VGLL1 overexpressing cells migration in comparison to VGLL1-negative cells, by
performing a wound healing assay. Cells were plated at 500,000 cells per well in triplicates
in the Cytoselet wound healing plates (Cell biolabs, Cat.#CBA-120). Each well contained a
pre-placed insert that creates 0.9mm gap for measuring migratory cells. After 24hrs the insert
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was removed and migration of the cells were observed for an additional 48hrs. At the 48hr
mark, VGLL1 over-expressing cells had nearly filled in the entire wound area (Figure 4.7A).
While WT and GFP-transduced control PANC1 cells, had migrated at a significantly slower
rate (Figure 4.7A). By analyzing multiple images and comparing the wound-healing area, we
concluded that the VGLL1-expressing cells migrated significantly faster than the other two
cell lines, P>0.0001 (Figure 4.7B). We also noted again in this assay that VGLL1transduced cells formed clusters that grew in three dimensions.
Based on the survival data of pancreatic and basal-like breast cancer patients (Figure
3.5 and 3.6), we reasoned that VGLL1 may have an effect on the aggressiveness of tumors in
vivo [154]. We next set out to determine if VGLL1 expression increased the invasiveness of
tumor cells in vitro. The invasiveness of a cell is determined by its ability to degrade and
migrate through an extracellular membrane barrier. We utilized PANC1 VGLL1overexpressing cells, along with WT parental, and GFP transduced controls cells. The
CHEMICON cell invasion kit by Millipore was used to conduct this assay. An invasion
chamber, containing a thin layer of an extracellular membrane (ECM) was inserted into a
well. The cells were placed inside of the invasion chamber in serum-free media, and RPMI
with 10% FBS was placed into the well below. The tumor cells were plated at 50,000 cells
per well and allowed to migrate for 48hrs. At the 24 and 48hr mark, cells attached to the
ECM were harvested. The invasive cells were stained and dried, following the collection of
the chambers, and counted by microscopy. The assay was performed in triplicates, a mean of
all invasive cells was derived from total cell counts. As shown, PANC1 VGLL1-expressing
cells had significantly more invasive cells than VGLL1 non-expressing PANC1 parental cells
(Figure 4.8A). Quantification of the total cells counts indicated that VGLL1-expressing
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cells demonstrated >10X the number of invasive cells after 48hrs, P >0.0001 (Figure 4.8B).
This data provides strong evidence that VGLL1 expression can drive tumor cell invasiveness,
and is consistent with the poor survival noted in patients with tumors demonstrating high
VGLL1 expression.
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VGLL1 protein expression in a pancreatic
and lung cancer line

FIGURE 4.4. Transduction of VGLL1 in two negatively expressing cell
lines.
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Figure 4.4. Transduction of VGLL1 in two negatively expressing cell lines. VGLL1 was
transduced in the pancreatic line, (A) PANC1 and the lung cancer line, H1975 (B). The lung
cancer line, H1975 was also knocked down by esiRNA following overexpression.
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H1975 tumor cell lines

Figure 4.5. VGLL1 induces morphology changes following transduction
in lung cancer cells.
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Figure 4.5. VGLL1 induces morphology changes following transduction in lung cancer
cells. VGLL1 was transduced into H1975 lung cancer cells. At 72hrs, the cells were analyzed
by microscopy for morphological changes. (Shown 10X left, 100X right) No differences
were seen in PANC1 (A) Parental, (B) GFP after 72 hrs. Following transduction, (C)
VGLL1-expressing cells formed spherical colonies that were not observed in the untransduced WT cell line. (D) Knockdown cells retained the same phenotype of the parental
and GFP cells.
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Proliferation of H195 tumor cells

Figure 4.6 Total cell counts of H1975 tumor cells.
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Figure 4.6 Total cell counts of H1975 tumor cells. Cells were played in
triplicates on day 1 at 30,000 cells per well. Each day, the cells were
harvested, counted, and the totals were then averaged. Total cell counts were
averaged and compared to day 1 (24hrs) for fold change in GraphPad. Data is
shown as mean ± STD *P <0.05 , **P<0.01.
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The effect of VGLL1-overxpression on
PANC1 tumor cells migration

Figure 4.7 VGLL1 increases migration of PANC1 tumor cells following
transduction.

152

Figure 4.7 VGLL1 increases migration of PANC1 tumor cells following
transduction.
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Figure 4.7. VGLL1 increases migration of PANC1 tumor cells following transduction.
(A, B) Representative image of the effect of VGLL1-overpexressing on the migration of
PANC1 tumor cells. Cells were plated in triplicates, and the area of the wound was
measured for all the fields of each well using Image J. Total migrated cell counts were
averaged in GraphPad. Data is shown as mean ± STD *P<0.05 , *** P< 0.001.
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Figure 4.8. VGLL1 Transwell Invasion Assay.
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FIGURE 4.8. PANC1 Transwell Invasion Assay. (A) Representative microscopic images of cells that
migrated through the extra cellular matrix layer and clung to the bottom of the polycarbonate membrane.
Cells were plated on the same day for two time points, 24hr and 48hr at 50,000 cells per well. The cells
were harvested at each time point. (B) The quantification of the invasive cells was performed using image
J for total migrated cells. Data from triplicates was averaged and analyzed by graphpad prism. Data is
shown as mean ± STD ****P<0.0001.
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4.4.) Discussion
The Hippo signaling pathway plays a critical role in cancer progression through the
oncogenes YAP and TAZ [178]. These two genes are co-transcriptional activators to the
TEADs within the Hippo signaling pathway. Cancers highjack this pathway and induce the
expression of YAP/TAZ to promote downstream target gene expression that promotes the
hallmarks of cancer [185]. These include genes involved in tumor cell proliferation,
migration, and invasion [169, 179, 185]. Since VGLL1 shares considerable homology to
YAP/TAZ, this prompted us to explore VGLL1’s potential role in also increasing these
‘hallmarks of cancers”.
Through these studies, we were able to show that VGLL1 expression induces distinct
morphological changes in pancreatic and lung tumor cells. The overexpression of VGLL1
induced both PANC1 and H1975 cells to exhibit aberrant growth patterns, in which cells
grew in multiple small clusters with some attached and others detached from the culture
plates. Despite being grown in 2D culture in traditional monolayers, the cells appeared to
acquire the ability grow more like that of 3D culture cells. This differed significantly from
what was observed in the parental and GFP-transduced tumor cells that retained normal
growth patterns. This strongly suggests that VGLL1 does have a direct impact on tumor cell
growth. VGLL1 can induce anchorage-independent growth in VGLL1-transduced prostate
tumor cells [163, 189]. This pattern of growth is a marker used to assess the metastatic
potential of tumors [186]. Malignant cells often acquire the ability to detach and continue to
grow and proliferate without being attached to a substrate. The next step would be to perform
a soft agar colony formation assay with VGLL1- transduced tumor cells. This assay
specifically analyzes anchorage-independent growth and will help confirm this phenotype.
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We showed that VGLL1 expression increased the proliferation rate of H1975 lung
tumor cells (Figure 4.6). Furthermore, VGLL1 expression also significantly increased the
migration and invasion of PANC1 pancreatic tumor cells (Figure 4.8). These results suggest
that VGLL1 can induce many of the same phenotypes in tumor cells as YAP/TAZ.
Additionally, according to the TCGA, VGLL1 and TAZ are not co-expressed, but rather are
mutually exclusive. Since, VGLL1 is thought to compete for binding to the TEADs with
YAP/TAZ, it may play a redundant role in cancer. However, more studies remain to be done
to elucidate its role in cancer progression.
Moving beyond in vitro studies into mouse models will be necessary to answer many
remaining questions. Mouse VGLL1 overexpression and knockdown plasmids have been
prepared to transduce mouse cell lines. It is also important to note that mouse and human
VGLL1 do not totally share overlapping symmetry; they only share 41% homology. The
mouse VGLL1 protein sequence is also nearly twice as long the human VGLL1. Therefore,
there may be some differences in their functions, but this still needs to be determined. Since
human placenta has the highest expression of VGLL1, it will be important to determine if
this is also the case in mice. Mouse placenta mRNA sequencing is planned to explore this
question. Additionally, RNA sequencing and Nanostring of a panel of human and mouse
tumor cell lines will be useful to determine what signaling pathways or genes may be
associated with VGLL1 expression. The studies in this dissertation have revealed some
intriguing results in vitro, but in vivo studies could substantially increase the significance of
these results. Based on the current findings, VGLL1 appears to play a role in cancer
progression similar to YAP/TAZ, but could also perform additional tasks that have yet to be
discovered.
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CHAPTER V:
OVERALL CONCLUSIONS AND FUTURE DIRECTIONS
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V. Overall Conclusions and Future Studies.
5.1 Overall Conclusions
One of the major objectives of this dissertation was to identify a shared, targetable
TAA to facilitate the development of a novel T cell based immunotherapy. By utilizing HLA
immunoprecipitation, peptide elution, and MS-based tumor antigen discovery, we were
successful in achieving our goal. Through our initial efforts working with ovarian tumor
specimens, we identified a HLA-B*07:02-restricted MUC16-derived peptide. This MUC16derived peptide, TPPGTQRSL, appeared to have great potential as a TAA (Table 2.3).
However, after attempts at T cell generation failed, we opted to stop pursuing this antigen as
a target (Figure 2.9 and 2.10).
T cell tolerance may be the reason why our efforts to generate T cells against MUC16
were unsuccessful. MUC16 is one of the largest surface glycoproteins at >22,000 amino
acids. It also contains many tandem repeats that are shared among other surface mucins.
Since MUC16 is primarily found in low abundance in female reproductive tissues, we
utilized healthy male donor PBMCs in our attempts to try to isolate MUC16-specific T cells.
While we were unsuccessful at expanding MUC16-specific T cells from this one male
donor, it is possible that other donors would have given a different outcome. There is
evidence that MUC16 peptides can be immunogenic, as shown in other studies [107].
However, cross-reactivity with other self-antigens may still be an issue should MUC16specific T cell generation be successful in the future.
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Since we also were working with pancreatic cancer tumor specimens simultaneously,
we identified the novel epitope, LSELETPGKY, derived from the cancer placenta antigen
VGLL1 (Table 3.1). This peptide was found in a pancreatic-patient derived tumor organoid
cell line. This added to the novelty of our finding, because there are only a few established
cancer-placenta antigens previously discovered [165]. Thus, VGLL1 is likely the first cancer
placenta antigen to be targeted clinically with T cell based immunotherapies.
VGLL1 peptide specific CTLs were generated from this same patient, and expanded
to >20 billion cells. This demonstrated that VGLL1 was immunogenic, further adding to its
potential as TAA target. These cells were administered to the patient as a treatment, but by
the time they received the T cells, the patient had lost tumor VGLL1 transcript expression
(Figure 3.13). Despite the patient’s loss of the VGLL1 gene target, this infusion showed that
there were no adverse effects or toxic effects from receiving the VGLL1-specific T cells.
Further work revealed VGLL1 to be a promising shared TAA not just for pancreatic,
but for multiple other cancers; including ovarian, bladder, lung, and breast cancers. We
showed that VGLL1-specific T cells show minimal recognition of primary cell lines, with the
exception of mammary cells. This may be the one area of caution for treatment of patients.
However, the infused patient did not experience any apparent toxic off target reactivites, so
this may not be a serious issue as our in vitro killing assay would suggest. Since, VGLL1 has
now been approved for an MD Anderson clinical trial of ETC we will know soon if toxicities
are seen in treated other patients.
The identification of VGLL1 also presented many additional questions pertaining to
its role in cancer progression. As previously stated, very few studies have been published on
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VGLL1 and most did not directly assess its function in cancer development. VGLL1 has
minimal expression in normal tissues, with the exception of the placenta where it is
expressed at over 200 TPMs on average (Figure 4.1) VGLL1 is expressed in
cytothrophoblasts within the placenta, these cells are the responsible for implanting the
placenta in the uterus, and forming the critical blood supply from the mother to the fetus
[171]. Due to the function and nature of cytothrophoblasts, we speculate that VGLL1 may
be involved in driving its high proliferation and invasive behavior.
Additionally, VGLL1 shares a similar binding motif to the well-characterized
oncogenes YAP/TAZ, within the Hippo signaling pathway [169, 187]. This signaling
pathway is the key regulator of organ size and development [184]. It appears that VGLL1
may compete for binding to the TEAD family of genes with YAP/TAZ. Once either of these
genes bind to the TEADs, they act as co-transcriptional activators, inducing the expression of
different cancer-promoting genes [174]. YAP/TAZ are linked to pancreatic, lung, and breast
cancer progression by promoting factors that increase EMT transition, proliferation,
chemoresistance, and immune evasion [169, 185, 190].
VGLL1 was specifically shown to upregulate anchorage-independent proliferation in
a prostate cancer cell line following transduction [187]. Anchorage-independent growth is a
key trait in cells transitioning into a metastatic state [186]. TAZ induces the migration,
invasion, and tumorigenesis of breast cancer cells through the Hippo pathway [182]. Since
VGLL1 may share similar characteristics to YAP/TAZ in the Hippo pathway, this led us to
explore if VGLL1 expression could also induce a similar phenotype in pancreatic tumor
cells. VGLL1 transduction indeed increased proliferation, migration, and invasion of
pancreatic tumor cells (Figure 4.5-4.8). These provide evidence supporting the idea that
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VGLL1 may play a role in driving cancer progression as well. We hypothesize that VGLL1
may be important for tumor cell proliferation and invasion early in tumorigenesis. This
hypothesis is partly based on the observation of the pancreatic patient losing VGLL1
expression overtime, despite having high expression early on. We believe that VGLL1 may
not be an essential driver in cancer, but rather an initiator, or potentially a stress dependent
response. We observed in that cells that became close to 100% confluent in culture
experienced a period of “crashing”, and slow recovery after being re-plated. However, after
that initial period they proliferated quickly again and became confluent. We think this may
be due to VGLL1 expression being turned on only when it is needed for migration, but when
cells begin to come in close contact, VGLL1 is downregulated to halt the growth of the
tumor cells. This mechanism could be used by tumors to slow growth when space and
resources become scarce, such as in low-nutrient environments. VGLL1-signaling in the
Hippo pathway may be downregulated and other pathways may be upregulated to support the
tumor during this time. The tumor microenvironment of pancreatic cancer controls abundant
stroma that contribute to fibrosis, which limits oxygen and nutrients for the tumor cells [191].
Pancreatic tumor cells turn on scavenging pathways in order to survive these environments,
and continue to thrive in times of low nutrients [191]. However, this is just one of the many
possible explanations of for the aberrant changes in VGLL1 expressing-tumors in vitro.
Performing experiments with mouse tumor models is the ideal next direction for our VGLL1
studies, in order to determine in vivo relevance.
5.2 Future Directions
To better understand the role of VGLL1 in disease progression, studying rare cancers
that arise during gestation may help shed light on VGLL1’s role in tumorigenesis.
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Gestational trophoblastic disease (GTD) is a rare group of tumors that develop in the placenta
during early pregnancy. These tumors includes invasive moles, choriocarcinoma (CCA), and
the more aggressive placental site trophoblastic tumor and epithelioid trophoblastic tumor
(PSTT/ETT) [192]. These tumors occur in due to abnormal growth of trophoblasts.
Currently, the mechanism behind the development of these caners at a molecular level
remains unknown. Since we know that VGLL1 is highly overexpressed in trophoblasts, and
is likely important for the invasive nature of trophoblasts during the development of placenta,
there may be a connection between VGLL1 expression and GTD development during
pregnancy.
One of the ways we could access the role of VGLL1 in GTD is to examine a cohort of
GTD patient tumor samples, and perform IHC staining to compare VGLL1 expression in
normal placenta vs. GTD patient tumors. We could determine if VGLL1 is expressed more in
GTD patient’s vs normal tissue donors. This would aid in determining if VGLL1 is important
for the initiation of GTD tumors. By identifying if VGLL1 is highly overexpressed in these
tumors, we could next determine what is causing the aberrant expression of VGLL1 in the
trophoblasts. We could achieve this by accessing if mutations within the Hippo signaling
pathway may be connected to the activation of VGLL1 signaling by looking at upstream
signaling partners of VGLL1 within in the Hippo pathway.
By performing genetic analysis on tumor samples, this may provide more in-depth
insight into the mutational changes occurring that lead to what may be the constitutive
activation Hippo signaling pathway mediated by VGLL1 upregulation. We could utilize RTPCR or Real-Time PCR to look for mutations at the RNA level. We could also access
differences at the DNA level, by performing micro array. In addition to looking specifically
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at VGLL1, we could also determine if other major players may be involved in the initiation
of GTD, such as YAP/TAZ, within in the Hippo signaling pathway.
Once targets have been identified, we could confirm their involvement with small molecule
inhibitors of the Hippo signaling pathway to determine if proliferation of GTD tumor cells is
reduced. By performing these set of studies we may be the first to show how GTD tumors
arise and provide alternative forms of treatments for patients that fail to response to the front
line therapy.
One approach to analyze proliferation, and migration, invasion would be to utilize an
immunodeficent mouse model in which human VGLL1-expressing and non VGLL1expressing tumors can be grown, monitoring the tumor site and metastasis over time. It will
require more extensive studies to assess the role of VGLL1 in immune evasion that we
cannot be explored in immunodeficent mice. Development of a mouse model to study
VGLL1 function in vivo is currently in the very early stages. We have the plasmids
constructed to create mouse VGLL1 overexpressing and knockdown cell lines. We have 3
different human pancreatic tumor lines that have been transduced to overexpress VGLL1,
and human placenta cells that we plan to use for comparison of pathways associated with
VGLL1 in primary tissues. Additionally, we are planning to explore pathways and gene
expression that may be connected to mouse VGLL1 expression by utilizing nanostring and
RNA sequencing. Nanostring and RNA sequencing will provide insights into the molecular
mechanisms controlling VGLL1 expression or what is being controlled by VGLL1
expression. There is still so much to left to learn about VGLL1, and we still very much in the
early stages of uncovering the significance of VGLL1 in cancer progression.
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Together, this dissertation has unveiled a novel shared TAA that shows great promise
as a therapeutic target for multiple cancers. VGLL1 is relatively uncharacterized in cancer,
but its homology to YAP/TAZ makes a compelling case to continue studies of this gene. If
the role of VGLL1 in in cancer progression cancer can be determined, it may open the door
to additional upstream or downstream therapeutic targets of VGLL1.With much to be
discovered, it is a very exciting point in research on VGLL1. We hope work will continue to
build on the foundation outlined in this dissertation, and in turn affect cancer patient’s lives
for the better in the future.
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CHAPTER VI:

MATERIALS AND METHODS
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Cell Lines. Human cancer cell lines demonstrating VGLL1 mRNA expression were
identified using the Cancer Cell Line Encyclopedia (CCLE) microarray-based gene
expression analysis. HLA-A*0101-expressing cancer cell lines PANC10.05, CAPAN-1
OAW28, HT1197, HT1376, BXPC3, UBCL-1, and primary cell lines were obtained from
commercial sources (ATCC and Sigma-Aldrich). Two VGLL1 negative cells lines were also
collected, the pancreatic cell line PANC1 and the lung cancer line H1975 was obtained from
(ATCC). The patient-derived organoid cell line MP015-Org (hMIA2D) was generated by the
Tuveson lab at Cold Spring Harbor Labs as previously described (29599906). The patientderived organoid cell line MP081-Org was generated by the Maitra lab from tumor tissue
derived from a wedge biopsy. The gastric cancer cell lines GT-5 and MKN74 were a kind
gift from Dr. Lee Ellis. WM793, MKN74, PANC1005, GT-5, and OAW28 cells were
cultured in RPMI 1640 medium (GIBCO), containing 10% fetal bovine serum, 1% penicillinstreptomycin (Pen-Strep) (Cellgrow), and 1% Insulin-Transferrin-Seleum-A (GIBCO). BT20
and bladder cell lines were cultured in equal parts DMEM F12K and MEM Alpha, with FBS,
Pen-Strep, and 1% sodium pyruvate (GIBCO). All other cell lines were cultured in RPMI
1640, FBS, and Penn-strep, with the addition of HEPES (GIBCO) and Glutamax (GIBCO).

Lentiviral Transductions. Some HLA-A*0101-negative tumor cell lines that naturally
expressed VGLL1 protein were transduced with a lentiviral gene transfer vector to express
HLA-A*0101 driven by the human PGK promoter, as previously described [193]. Ectopic
cell surface expression of A*0101 was assessed by staining with anti-human HLA-A1-biotin
and streptavidin-FITC (US Biological) and measuring fluorescence using a FACScanto II
flow cytometer (BD Biosciences). Tumor cells expressing physiological and comparable
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levels of surface HLA-A*0101 were isolated by cell sorting and used in subsequent
experiments. To conduct proliferation and invasion assays WT cell lines with no VGLL1
expression were compared to lenti-viral overexpressed cell lines. For cell lines with no
VGLL1 expression, the origene plasmid was used to generate a lentivirus (RC600200L1V,
Origene). WT VGLL1 negative cell lines were transduced to express VGLL1 and protein
expression was validated by western blot analysis.

VGLL1 Protein Expression. VGLL1 protein expression was confirmed in all cell lines by
Western blot analysis. Cell lysates from tumor and primary cell lines were prepared and
protein content normalized using the BCA method (Thermo-Fisher). Using standard Western
blot techniques, cell lysates were run by polyacrylamide gel electrophoresis, transferred, and
membranes probed with VGLL1-specific rabbit polyclonal antibody (TA322329, OriGene).
VGLL1 protein was visualized using an enzyme-linked anti-rabbit mAb with the Scientific
Pierce Fast Western Blot Kit, according to the manufacturer’s instructions.

Peptide Identification, Selection and Validation. Patient-derived laparoscopic wedge
biopsies, xenografts (PDX), or cell lines were lysed using Triton X-100 and cell lysates
incubated overnight at 4oC with 1µg of pan-HLA-ABC specific mAb W6/32 for every 10 mg
of protein. Protein A/G Ultralink resin beads were used to immunoprecipate HLA class I
molecules and HLA-bound peptides were then eluted with 0.1M acetic acid. HLA-A,B,C
isolation was confirmed by Western blot analysis, then HLA-positive elutes were analyzed
by tandem mass spectrometry (MS/MS). HLA class I protein recovery was semiquantitatively assessed by rating Western blot band intensity on a scale from 0 (not
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detectable) to 4 (highest intensity). Tumor-associated HLA-bound peptides were injected
onto HPLC system (Dionex 3000 RSLC), and separated by reverse-phase chromatography in
0.1% formic acid water-acetonitrile on 1.8µm C18 (Agilent Technologies) in the MS/MS
discovery phase. Peptides were analyzed on an Orbitrap Elite mass spectrometer (ThermoFisher) using data-dependent acquisition. To analyze the acquired MS/MS spectra, the
Mascot algorithm was utilized to search the spectra against the SwissProt complete human
protein database (updated 9/2018), which provided potential matches to conventionally
annotated peptides.
Individual peptide matches underwent quality assessment by reference to multiple
orthogonal parameters, including Mascot Ion score, MS1 measured differential to the
calculated peptide mass (delta mass), and predicted binding to the patient’s HLA allotypes as
determined by high-resolution genetic sequencing and the NetMHC and NetMHCpan
algorithms [100],[101]. High-confidence peptide matches were analyzed by BLAST
searches to identify all potential source genes, which were then cross-referenced to RNAseq
data derived from individual tumor samples to provide further validation of peptide identity
(validation requiring a minimum source gene expression of 0.3 transcripts per million, TPM).
Eluted TAA peptides were screened for safety as potential CTL targets by applying
sequential RNA transcript expression filters to eliminate peptides most likely to elicit
autoimmune toxicities due to normal tissue expression (GTex Portal RNAseq data,
http://cancergenome.nih.gov/). Excluding testis and placenta, source gene transcript
expression of 30 TPM maximum was allowed in non-essential tissues (listed in Table S2), 10
TPM in “caution” tissues, 3 TPM in “hazard” tissues and 1 TPM in highly essential “danger”
tissues (such as heart and brain). Putative TAA genes were also screened for expression and
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prevalence in different cancer types through analysis of TCGA RNAseq data
(http://cancergenome.nih.gov/). In selected cases, targeted-MS/MS analysis was performed to
confirm TAA peptide identity. For these analyses, retention-time windows for 13C/15N
isotope-labeled synthetic peptide standards were pre-determined by MS analysis of the
synthetic peptides, then targeted methods for searching TAA peptides were constructed using
mass windows of 3 Da around each m/z.

Gene Expression Analysis and Patient Survival. Whole transcriptome sequencing
(RNAseq) analysis was performed on RNA derived from all PDAC tumor specimens,
xenografts, and organoid cell lines using the Illumina TruSeq Stranded Total RNA kit with
Ribo-Zero Gold with approximately 200 million paired-end reads for each tumor RNA
sample (Avera Institute for Human Genetics). Gene expression profiles of VGLL1 and other
cancer placenta antigens were determined by compiling RNAseq data derived from normal
human primary tissues (GTex Portal) and tumor tissues (TCGA). Kaplan-Meier curves were
generated from survival data of TCGA cancer patients when stratified by tumor VGLL1
transcript expression.
Isolation and expansion of antigen-specific CD8 T cells. We generated three antigenspecific T cells. A MART-1 HLA-A*0201 restricted peptide was used as our control antigen.
The MUC16 B0702-restricted peptide TPGGTRQSL, and the VGLL1 peptide HLA-A*0101
restricted peptide LSELETPGKY were both our experimental test antigens. Antigen–
specific CTLs were generated as previously described [194], [195], [196]. To generate T
cells against both the A2-restricted MART-1 derived peptide, and MUC16 B7-restricted
peptide, we begin with the same healthy donor. This donor was both HLA-A2*0201 and
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HLA-B*0702 positive. We isolated PBMCs from this healthy-donor. PBMCs derived from
this this donor were stimulated in separate wells by MART-1 peptide and B7-restricted
MUC16 peptide. After the stimulation, cultured cells were stained with either an MART1/HLA*0201 or MUC16/HLA-B*0702-PE conjugated custom tetramer. (Fred Hutchinson
Cancer Research Center), washed and then stained with APC-conjugated CD8 antibody.
Cells were washed and analyzed by flow cytometry (LSRFortessa X-20 Analyzer). CD8 and
tetramer double-positive cells were sorted by ARIA II and the VGLL1-specific CD8 T cells
were expanded using the Rapid Expansion Protocol (REP) with PBMC and LCL feeder cells,
as previously described.(16081794).
To generate VGLL1-specific T cells HLA-A*0101 positive patient- or healthy donorderived PBMCs were stimulated twice by autologous dendritic cells (DCs) pulsed with the
VGLL1231-240 peptide LSELETPGKY. Six days after the second DC stimulation, cultured
cells were stained with VGLL1231-240 peptide/HLA-A*0101–PE-conjugated custom tetramer
(Fred Hutchinson Cancer Research Center), washed and then stained with APC-conjugated
CD8 antibody. Cells were washed and analyzed by flow cytometry (LSRFortessa X-20
Analyzer). CD8 and tetramer double-positive cells were sorted by ARIA II and the VGLL1specific CD8 T cells were expanded using the Rapid Expansion Protocol (REP) with PBMC
and LCL feeder cells, as previously described.(16081794) The TCR Vβ repertoire of
expanded CD8 T cells was assessed using the IOTest Beta Mark TCR-Vβ Repertoire kit.
Cytotoxic T cell assays. Antitumor killing by VGLL1-specific CD8+ T cells was assessed
using a standard chromium-51 (51Cr) release assay. Target cells were labeled with 100µL of
51

Cr for 1 hour, then washed and plated at 2,000 target cells per well in triplicate. VGLL1172

specific CD8+ T cells were incubated with target cells at various effector-to-target (E:T) cell
ratios for four hours. After the incubation period, supernatant was collected from the wells
and 51Cr was measured with a gamma radiation counter. The percentage of specific target
cell lysis was calculated, correcting for background 51Cr release and relative to a maximum
51

Cr release as measured by Triton X-100 lysed target cells.

esiRNA Knockdown. VGLL1 knockdown cells were generated using MISSION
esiRNA (Cat. #EHU042561, Millipore). H1975-VGLL1 expressing cells were transfected
with esiRNA two months after VGLL1 transduction. The cells were re-assessed by western
blot analysis for VGLL1 over-expression prior to knockdown. 48hrs post-transfection, the
cells were checked by western blot analysis for knockdown. Once knockdown was
confirmed, they were immediately used in assays.

Proliferation Assays. H1975 VGLL1-transduced, GFP, and parental cells were plated in
triplicates at 30,000 cells per well. Each line was plated in wells marked 0hr, 24hr, 72hr, and
96hrs. At each time point the cells were collected and counted by Nexcelom Cellometer.
Cells counts were averaged at each time and the data was analyzed using graph pad prism.

Wound Healing Assay. The CytoSelect™ Wound Healing Kit from Millipore (Cat.# CBA120) was used to perform the wound healing assay. The kit contained well inserts that
created 0.9mm gaps. PANC1 VGLL1 transduced, GFP, and parental cell lines were plated at
and collected after 24hrs. 500,000 cells were collected in media and 500 µL of the cell
suspension was added to each well insert in triplicates. The cells were incubated overnight
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and sterile forceps were used to remove the well inserts. The media was changed and the
cells visualized under the microscope. We monitored the cells for an additional 48 hrs.,
taking images each day. Migration was assessed by the visualization and quantification of the
wound at multiple areas within the well for each day. Data was analyzed by Image J and
Graphpad Prism.
Transwell Invasion assays. Invasiveness of VGLL1 transduced, GFP, and parental
PANC1 cells was accessed with the use of the QCM ECMatrix Cell Invasion Assay
(Millipore Sigma, Cat. # ECM550). Cells were plated in triplicate in two time points,
24hr and 48hr at 50,000 cells per well in chamber inserts containing a thin-monolayer
of extracellular membrane. RPMI with 10% FBS media was added to the well below.
The cells were then left to incubate at their respective time points and were harvested
at each point. The cells were stained with crystal violet stain following washing a
cleaning of the ECM insert chamber. Cells attached to the ECM after washing were
counted by first visualizing under a microscope and photos were analyzed by Image J.
Cell count data was then further analyzed in Grahpad Prism.
Statistical analysis. Data analysis was performed using GraphPad Prism version 7.03.
Normally distributed data were analyzed using parametric tests (ANOVA or unpaired t test).
Kaplan-Meier survival curves were analyzed by log-rank tests. Test differences were
considered statistically significant if P<0.05.
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